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RESUMO 
 
Introdução: Os cancros da mama, colorretal e do pulmão são os três tipos de cancro mais 
comuns e mortais em mulheres de países desenvolvidos. O rastreio do cancro leva ao 
aumento do número de tumores detetados em estadios iniciais, estando, no entanto, 
associado a uma alta taxa de falsos positivos e ao tratamento de cancros possivelmente 
indolentes. A metilação aberrante do DNA é um fenómeno que ocorre cedo no 
desenvolvimento do cancro e que pode ser detetada em DNA tumoral circulante, 
constituindo um marcador promissor para a deteção precoce do cancro de uma forma não 
invasiva. Assim, este trabalho teve como principal objetivo desenvolver um teste sensível 
e específico baseado na metilação do DNA circulante extraído do plasma, para deteção 
simultânea dos cancros da mama, colorretal e pulmão. 
  
Métodos: O DNA circulante foi extraído de amostras de plasma provenientes de pacientes 
com cancro da mama, colorretal, do pulmão e dadores saudáveis, sujeito a modificação 
bissulfito e a uma amplificação. Os níveis de metilação dos promotores dos genes APC, 
FOXA1, MGMT, RARβ2, RASSF1A, SCGB3A1, SEPT9, SHOX2 e SOX17 foram 
determinados por PCR específico de metilação em multiplex. Foram avaliadas as 
associações entre os níveis de metilação e variáveis clinicopatológicas. A sensibilidade e 
especificidade foram também calculadas de forma a avaliar a performance diagnóstica dos 
biomarcadores.  
  
Resultados: O painel “PanCancer”, constituído por APC, FOXA1 e RASSF1A, detetou os 
três cancros mais frequentes nas mulheres com uma sensibilidade de 72% e uma 
especificidade de 74%, enquanto o painel “CancerType” (SCGB3A1, SEPT9 e SOX17) 
indicou com alta especificidade (superior a 80%) a possível origem do tumor, embora com 
baixa sensibilidade.  
  
Conclusões: A avaliação dos níveis de metilação em DNA circulante é uma estratégia 
promissora para o rastreio simultâneo dos cancros da mama, colorretal e do pulmão. Este 
teste tem o potencial para complementar os métodos atualmente usados, aperfeiçoar a 
triagem de indivíduos com suspeita de cancro, e aumentar a aderência aos programas de 
rastreio e o seu custo-efetividade.  
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ABSTRACT 
 
Background: Breast (BrC), colorectal (CRC) and lung (LC) cancers are the three most 
common and deadly cancers in women in developed regions. Cancer screening entails 
increase in early stage disease detection but is variably hampered by high false-positive 
rates and overdiagnosis/overtreatment. Aberrant DNA methylation occurs early in cancer 
and may be detected in circulating cell-free DNA (ccfDNA), constituting a valuable cancer 
biomarker and enabling non-invasive testing for early cancer detection. Thus, we aimed to 
develop a sensitive and specific ccfDNA methylation-based test for simultaneous detection 
of BrC, CRC and LC. 
Methods: CcfDNA from BrC, CRC and LC patients and healthy donors was extracted from 
plasma, sodium-bisulfite modified and whole-genome amplified. APC, FOXA1, MGMT, 
RARβ2, RASSF1A, SCGB3A1, SEPT9, SHOX2 and SOX17 promoter methylation levels 
were determined by multiplex quantitative methylation-specific PCR. Associations between 
methylation and standard clinicopathological parameters were assessed. Sensitivity and 
specificity were calculated to evaluate biomarkers’ diagnostic performance. 
Results: A “PanCancer” panel (APC, FOXA1 and RASSF1A) detected the three major 
cancers with 72% sensitivity and 74% specificity, whereas a “CancerType” panel 
(SCGB3A1, SEPT9 and SOX17) complemented the former, to indicate the most likely 
cancer topography, with over 80% specificity, although with limited sensitivity. 
 
Conclusions: Gene promoter methylation assessment in ccfDNA is promising for 
simultaneous screening of BrC, CRC and LC, complementing current screening modalities, 
perfecting the triage of cancer suspects, and increasing compliance and cost-effectiveness.  
 
 
 
 
 
 
 
 
 
 
 
 
 
x 
 
TABLE OF CONTENTS 
 
INTRODUCTION .............................................................................................................. 1 
EPIDEMIOLOGY .............................................................................................................. 2 
BREAST CANCER ........................................................................................................... 3 
Risk Factors ............................................................................................................... 3 
Screening and Diagnosis ........................................................................................... 4 
Histological Subtypes ................................................................................................ 5 
Staging ...................................................................................................................... 6 
Prognosis Factors ...................................................................................................... 6 
Molecular Subtypes ................................................................................................... 7 
Treatment .................................................................................................................. 8 
COLORECTAL CANCER ................................................................................................10 
Risk Factors ..............................................................................................................10 
Screening and Diagnosis ..........................................................................................10 
Molecular Pathways ..................................................................................................12 
Histopathology and Precursor Lesions ......................................................................13 
Staging .....................................................................................................................13 
Treatment .................................................................................................................14 
LUNG CANCER ...............................................................................................................16 
Risk Factors ..............................................................................................................16 
Screening and Diagnosis ..........................................................................................16 
Histological Subtypes ...............................................................................................18 
Staging .....................................................................................................................18 
Treatment .................................................................................................................19 
EPIGENETICS .................................................................................................................20 
DNA Methylation .......................................................................................................20 
Liquid Biospies .........................................................................................................22 
DNA Methylation-based Biomarkers .........................................................................23 
AIMS ................................................................................................................................28 
MATERIAL AND METHODS ............................................................................................30 
CLINICAL SAMPLES .......................................................................................................31 
Patients and Samples Collection ..............................................................................31 
Samples Processing .................................................................................................31 
Cell-free DNA Extraction ...........................................................................................31 
SODIUM-BISULFITE MODIFICATION ............................................................................32 
WHOLE GENOME AMPLIFICATION ...............................................................................33 
 
 
xi 
 
NUCLEIC ACID QUANTIFICATION .................................................................................34 
MULTIPLEX QUANTITATIVE METHYLATION SPECIFIC PCR ......................................34 
STATISTICAL ANALYSIS ................................................................................................36 
RESULTS ........................................................................................................................38 
Clinical and Pathological Data ..................................................................................39 
Gene Promoter Methylation Levels in ccfDNA ..........................................................41 
Association Between Promoters’ Methylation Levels and Clinicopathological Features
 .................................................................................................................................44 
Biomarker Performance of ccfdna .............................................................................46 
DISCUSSION ..................................................................................................................50 
CONCLUSION .................................................................................................................56 
REFERENCES ................................................................................................................58 
APPENDIX ........................................................................................................................ I 
APPENDIX I ..................................................................................................................... II 
Breast Cancer TNM Staging ...................................................................................... II 
APPENDIX II ................................................................................................................... IV 
Colorectal Cancer TNM Staging ............................................................................... IV 
APPENDIX III................................................................................................................... VI 
Lung Cancer TNM Staging ....................................................................................... VI 
APPENDIX IV .................................................................................................................. IX 
APPENDIX V .................................................................................................................... X 
APPENDIX VI .................................................................................................................. XI 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xii 
 
FIGURES INDEX 
 
Figure 1. Estimated percentage of (A) cancer-related incidence and (B) cancer-related 
mortality in women in developed regions in 2012. Adapted from (1). ................................ 2 
Figure 2. Early BrC treatment algorithm according to ESMO guidelines (2). Adapted from 
(2). Abbreviations: HT - Hormone therapy; RT - Radiotherapy .......................................... 9 
Figure 3. Definition of primary tumor (T) according to the 8th edition of AJCC Cancer 
Staging Manual for CRC staging. Nunes SP unpublished ................................................14 
Figure 4. Simplified algorithm of CRC treatment according to ESMO guidelines (54, 61, 62). 
Adapted from (63). *For rectal cancer treatment. .............................................................15 
Figure 5. Scheme of the diagnostic procedures depending on the lesion location in lung. 
Adapted from (6) Abbreviations: CT - Computed tomography; PET - Positron emission 
tomography. .....................................................................................................................17 
Figure 6. Four main epigenetic mechanisms involved in gene expression regulation. DNA 
methylation consists in an addition of a methyl group in cytosine present in a cytosine-
phosphate-guanine (CpG) dinucleotide. Histone post-translational modifications refer to 
alterations in histone tails such as methylation, acetylation, phosphorylation and 
ubiquitination that regulate gene expression. Histone variants differ few amino acids from 
canonical histones and regulate chromatin remodeling and histone post-translational 
modifications. Chromatin remodeling complexes regulate the nucleosome structure by 
removing, relocate and shifting histones. (Kindly provided by Lameirinhas A. unpublished)
 ........................................................................................................................................20 
Figure 7. CcfDNA liquid biopsy. Tumor DNA can have several origins, namely living tumor 
cells, apoptotic or necrotic tumor cells and circulating tumor cells (CTCs). Blood can be 
collected, the ccfDNA can be extracted from serum/plasma and analyzed in a context of a 
liquid biopsy. Nunes SP unpublished. ..............................................................................22 
Figure 8. Sodium-bisulfite modification of DNA. The unmethylated cytosines are converted 
to uracil, whereas methylated cytosines remain unchanged. Abbreviations: C – cytosine 
residue; mC – methylated cytosine residue; G – guanine residue; U – uracil residue; 5-mC 
– 5-methylcytosine. (Kindly provided by A. Lameirinhas unpublished) .............................32 
Figure 9. Scatter plot of the distribution of (A) APC, (B) FOXA1, (C) MGMT, (D) RARβ2, 
(E) RASSF1A, (F) SCGB3A1, (G) SEPT9, (H) SHOX2 and (I) SOX17 promoters’ 
methylation levels in BrC patients (n=108) and ACs (n=103). Mann Whitney Test, n.s. 
p>0.05, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. .....................................................41 
Figure 10. Scatter plot of the distribution of (A) APC, (B) FOXA1, (C) MGMT, (D) RARβ2, 
(E) RASSF1A, (F) SCGB3A1, (G) SEPT9, (H) SHOX2 and (I) SOX17 promoters’ 
 
 
xiii 
 
methylation levels between CRC patients (n=72) and ACs (n=103). Mann Whitney Test, 
n.s. p>0.05, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. Black horizontal line represents 
the methylation levels’ median. ........................................................................................42 
Figure 11. Scatter plot of the distribution of (A) APC, (B) FOXA1, (C) MGMT, (D) RARβ2, 
(E) RASSF1A, (F) SCGB3A1, (G) SHOX2 and (H) SOX17 promoters’ methylation levels 
between LC patients (n=73) and ACs (n=103). SEPT9 only presented zero values for AC 
and LC patients. Mann Whitney Test, n.s. p>0.05, *p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001. Black horizontal line represents the methylation levels’ median. ................43 
Figure 12. Scatter plot of (A) RASSF1A promoter’s methylation levels between positive and 
negative Progesterone Receptor (Negative n=24, Positive n=94) and (B) RARβ2 promoter’s 
methylation levels between node-negative and node-positive BrC patients (Negative n=65, 
Positive n=43). Mann Whitney Test, *p<0.05, **p<0.01. ...................................................44 
Figure 13. Scatter plot of (A) APC, (B) SEPT9, (C) SHOX2 and (D) SOX17 promoter’s 
methylation levels between metastatic CRC patients (M1) and non-metastatic CRC patients 
(M0) (M0 n=66, M1 n=6). Mann Whitney Test, *p<0.05, ****p<0.0001. ............................45 
Figure 14. Scatter plot of (A) APC and (B) RARβ2 promoters’ methylation levels for 
Histological Subtype (Adenocarcinoma n=55, SCLC n=8), (C) RASSF1A promoter’s 
methylation levels for Regional Node (N) status (Negative=27, Positive=45) and (D) SOX17 
promoter’s methylation levels between metastatic LC patients (M1) and non-metastatic LC 
patients (M0) (M0 n=36, M1 n=37). Mann Whitney Test, *p<0.05, **p<0.01. Black horizontal 
line represents the methylation levels’ median. ................................................................46 
Figure 15. Percentage of cases identified by “PanCancer” panel in cancer samples 
(Positive 72%, Negative 28%) and ACs (Positive 26%, Negative 74%). ..........................48 
Figure 16. Schematic representation of a proposed algorithm for screening and 
management of breast, colorectal and lung cancers using the methylation panels. If 
“PanCancer” panel positive, “CancerType” panel would be performed in order to determine 
the cancer type present. After “CancerType”, exams such as mammography, colonoscopy 
or low-dose computed tomography (LDCT) would be executed to confirm the diagnosis. If 
“PanCancer” panel negative, a re-screening would be proposed, whereas if “CancerType” 
panel negative, a clinical evaluation or a re-screening would be options. Nunes SP 
unpublished .....................................................................................................................55 
 
 
 
 
 
 
 
xiv 
 
TABLES INDEX 
 
Table 1. Guidelines for BrC screening from different agencies. ........................................ 5 
Table 2. BrC subtyping by IHC. Adapted from (2, 27). ...................................................... 8 
Table 3. Test performance of screening tests currently used for CRC screening. Adapted 
from (53). .........................................................................................................................11 
Table 4. Previously published methylation panels for BrC detection in ccfDNA liquid 
biopsies. ..........................................................................................................................24 
Table 5. Previously published methylation panels for CRC detection in ccfDNA liquid 
biopsies. ..........................................................................................................................26 
Table 6. Previously published methylation panels for LC detection in ccfDNA liquid biopsies.
 ........................................................................................................................................27 
Table 7. Number of plasma samples of the BrC, CRC, LC patients and ACs...................31 
Table 8. Primers and probes sequences with respective fluorochrome and quencher. ....34 
Table 9. Gene combinations for multiplex qMSP. ............................................................35 
Table 10. Formulas for biomarkers performance calculations. Abbreviations: PPV – Positive 
Predictive Value; NPV – Negative Predictive Value. ........................................................37 
Table 11. Clinical and pathological features of BrC, CRC and LC patients and ACs enrolled 
in this study. .....................................................................................................................39 
Table 12. Biomarker performance of each promoter’s gene methylation for BrC, CRC and 
LC detection in ccfDNA. ...................................................................................................47 
Table 13. Biomarker performance detection of “PanCancer” panel (APC, FOXA1 and 
RASSF1A) in ccfDNA. .....................................................................................................48 
Table 14. Methylated gene promoter combinations for BrC, CRC and LC discrimination 
using the “CancerType” panel. .........................................................................................49 
Table 15. Performance of gene promoter combinations for discrimination among BrC, CRC 
and LC (“CancerType” panel). .........................................................................................49 
 
 
 
 
 
 
 
 
 
 
xv 
 
LIST OF ABBREVIATIONS 
 
AC – Asymptomatic control 
ACS - American Cancer Society  
AJCC - American Joint Committee on Cancer 
ALK - Anaplastic lymphoma kinase 
APC – Adenomatosis polyposis coli  
BrC - Breast cancer  
BRCA - DNA repair associated 
CcfDNA - Circulating cell-free tumor DNA  
CEA - Carcinoembryogenic antigen  
CIMP - CpG island methylator phenotype  
CIN - Chromosomal instability  
CpG - Cytosine-phosphate-guanine 
CRC – Colorectal cancer 
CT - Computed tomography  
CTCs - Circulating tumor cells  
DCIS - Ductal Carcinoma In Situ  
DNMT - DNA methyltransferase 
ER - Estrogen receptor 
EGFR - Epidermal growth factor receptor   
ERBB2 - Erb-B2 receptor tyrosine kinase 2 
ESMO - European society for medical oncology  
FAP – Familiar adenomatous polyposis 
FISH - Fluorescence in situ hybridization  
FIT - Feacal immunochemical test  
FNA - Fine-needle aspiration  
FOBT - Faecal occult blood testing 
FOXA1 – Fork-head box A1 
gFOBT - Guaiac-based faecal occult blood testing 
LC – Lung cancer  
LCIS – Lobular carcinoma in situ 
LDCT - Low-dose computed tomography  
HER2 - Human epidermal growth factor receptor 2 
HNPCC – Hereditary nonpolyposis colorectal cancer 
HT – Hormone therapy 
IHC - Immunohistochemistry  
 
 
xvi 
 
MBP - Methyl-CpG-binding protein 
MDA – Multiple displacement amplification  
MGMT – 6-methylguanine DNA methyltransferase  
MMR - Mismatch repair 
MRI - Magnetic resonance imaging  
MSI - Microsatellite instability 
NELSON - Dutch-Belgian Lung Cancer Screening Trial  
NNK - 4-(methylnitrosamino)-1-(13-pyridyl-1-butanone)  
NLST - National Lung Screening Trial  
NPV – Negative predictive value 
NSCLC - Non-small cell lung cancer   
NSAIDS - Nonsteroidal anti-inflammatory drugs  
PD-L1 - Programmed death-ligand 1  
PET - Positron emission tomography  
PPV – Positive predictive value 
PR – Progesterone receptor  
qMSP – Quantitative methylation-specific PCR 
RARβ2 – Retinoic acid receptor beta 2 
RASSF1A – Ras association domain family 1 isoform A  
ROS1 - Proto-oncogene tyrosine-protein kinase ROS  
RT – Radiotherapy 
SCGB3A1 – Secretoglobin family 3A member 1  
SCLC - Small cell lung cancer 
SEPT9 – Septin 9 
SHOX2 – Short stature homeobox 2  
SOX17 – Sex determining region Y box 17 
SSC – Special subtype carcinoma 
TET - Ten-eleven methylcytosine dioxygenase 
TNBC - Triple-negative breast cancer 
TP53 - Tumor Protein p53  
UICC - Union for International Cancer Control 
USPSTF - US Preventive Services Task Forces  
VEGF – Vascular endothelial growth factor  
WGA – Whole genome amplification 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION
 
 
INTRODUCTION|2 
 
EPIDEMIOLOGY  
 Breast cancer (BrC) is the most incident cancer in women in developed regions, 
followed by colorectal cancer (CRC) and lung cancer (LC) (Figure 1A) (1). Regarding 
cancer-related mortality, BrC is the second cause of death after LC in developed regions 
(1) (Figure 1B). Moreover, BrC incidence continues to increase mainly due to improvements 
in mammography screening (2).  
 
Figure 1. Estimated percentage of (A) cancer-related incidence and (B) cancer-related mortality in women in 
developed regions in 2012. Adapted from (1). 
 LC is the most common cause of cancer-related death worldwide and the first in 
women from developed regions (Figure 1B) (1). Nevertheless, women’s incidence rates are 
lower when compared to men, although it increased throughout the recent years (1). A 
geographical pattern is verified in women’s LC incidence, which can be a consequence of 
tobacco consumption, since LC rates are higher in Northern America and Northern Europe 
when compared with Western Europe and Middle Africa (3). The majority of the LC cases 
are diagnosed at advanced stages (approximately 75%) and associate with a 5-year 
survival of 10% (4). 
 CRC is the second most common type of cancer in women, accounting for 9.2% of 
women’s cancer cases worldwide and the third cause of death in developed regions (Figure 
1B) (1). Although 55% of CRC cases occur in more developed regions (5), CRC mortality 
has been decreasing in these regions due to the implementation of colonoscopy screening 
(1). 
 In Portugal, 29.4% of cancer cases in women are BrC cases, with an associated 
mortality rate of 16% and a prevalence of 40% (1). CRC is the second most common and 
deadly type of cancer, whereas LC is the 5th most incident and the 4th cause of cancer-
related death (1). 
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BREAST CANCER 
 
RISK FACTORS  
 Several risk factors are associated with increased risk for BrC development, 
including advanced age, exposure to female hormones, reproductive history, family history 
and environmental aspects (6). The risk for BrC cancer rises with age (7), although this 
effect is greater in premenopausal women, since the risk for developing BrC is higher than 
in postmenopausal (7). 
 Hormonal factors modulate BrC risk (8). Specifically, late menarche and an early 
menopause are associated with reduced BrC risk (7). Conversely, hormone replacement 
therapy increases the risk of BrC development in 24%, as well as the use of oral 
contraceptives (9). The risk for BrC development is also associated with reproductive history 
(6): nulliparous women have a higher relative risk of BrC development than parous women 
(6). Indeed, the greater the number of births, the less risk of developing BrC (9), as 
breastfeeding has a protective effect on BrC and the benefit is higher the longer the 
breastfeeding period (7). 
 Family history of BrC is a recognized risk factor for BrC (6, 7). Women with a first 
degree relative with BrC have a risk 1.5-3 times higher to develop BrC (6). BrC associated 
with DNA repair associated 1 (BRCA1) and 2 (BRCA2) germline mutations account for 5-
10% of all BrC cases (6). Women with BRCA mutations have a risk up to 85% of BrC 
development, being generally younger and premenopausal (6). Hereditary syndromes such 
as Li-Fraumeni, associated with tumor protein p53 (TP53) mutation, and Cowden Syndrome 
(PTEN mutation) also increase the BrC risk (6). Benign breast disease, namely proliferative 
lesions with atypical hyperplasia are associated with a relative risk of 4.0 to 5.0 to develop 
BrC (6).  
 Environmental factors such as radiation exposure and diet have been associated 
with BrC. Radiation exposure by image exams [annual mammography exam associated 
with 86 cancers per 100,000 women (10)] and therapeutic irradiation [for example, for 
Hodgkin’s lymphoma treatment at younger ages is associated with a 48% BrC risk (11)] 
increase the risk of BrC development (6, 7). Additionally, alcohol consumption and fat intake 
have been also associated with BrC development (7). Indeed, weight gain and obesity in 
post-menopausal women are associated with a 1.25 relative risk of BrC development (9).  
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SCREENING AND DIAGNOSIS  
 As stated earlier, BrC is the most diagnosed cancer in women, with increased   
incidence after the implementation of screening by mammography (12). Mammography is 
based on the usage of X-ray and allows for the identification of different densities, 
microcalcifications and asymmetries in the breast. For instance, multifocal fine 
microcalcifications are frequently associated with malignant tumors (13). Screening 
mammography detects BCa with 85% sensitivity and 90% specificity in elder women (14). 
However, the sensitivity decreases with the increase of breast density, with over 70% of the 
breast tumors missed in a dense breast (15).  
 The first clinical trial that showed the effect of screening mammography in BrC 
mortality started in 1963. Shapiro and its colleagues showed that mammography screening 
led to decreased deaths by BrC (16). In the following years several studies were conducted 
showing a mortality reduction ranging from 28% to 45% (17). In addition, screening 
mammography also allowed for tumor’s early detection, and consequent reduction of 
morbidity related to BrC treatments (18). Although BrC screening features several benefits, 
it presents important disadvantages. One of the major disadvantages is the overdiagnosis 
(13, 19). Indeed, 11% of the cases detected in a population invited to screening that would 
probably not be clinically relevant in the woman’s lifetime are treated (19). Another 
disadvantage that arises from the BrC screening are the false-positive results. These are 
more frequent in younger women, with ages between 40-49 years old, since the 
mammography sensitivity decreases in younger groups (20). False-positive results lead to 
extra imaging exams and eventually biopsies procedures, which can cause discomfort and 
anxiety to the subjects (19). Pain arising from the mammography and radiation exposure 
are other mentioned problems related to BrC screening (19, 21).  
 The BrC screening recommendations are not consensual: while mammography is 
the main exam used for BrC screening, the starting age the exams’ interval continues to be 
discussed (22). European Society for Medical Oncology (ESMO) guidelines suggest that 
mammography screening should start at the age of 50 and end at 69, with a screening every 
two years (Table 1) (2). In 2015, the American Cancer Society (ACS) updated the BrC 
screening guidelines indicating that BrC screening should start at 45 years old (Table 1). 
Nevertheless, women with ages between 40 and 44 should have the possibility to perform 
the annually screening (23). The US Preventive Services Task Forces (USPSTF) 
recommends a biennial screening in women between 50 and 74 years old (Table 1) (24) 
However, there is insufficient evidence about the benefits of BrC screening in women with 
age above 75 (21). In women with higher risk of BrC, i.e., with BRCA1/2 mutations or family 
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history of BrC, screening combining magnetic resonance imaging (MRI) and mammography 
every 6 months is currently recommended (2).  
Table 1. Guidelines for BrC screening from different agencies.  
Organization Age interval 
Interval between 
mammography 
ESMO 50-69 2 years 
ACS 
40-44 
Women should have the choice 
1 year 
45-54 1 year 
≥ 55 
Women should continue until is 
expected to live 10 more years or longer 
2 years 
USPSTF 
40-49 
Women should have the choice 
½ year 
50-74 ½ year 
Abbreviations: ESMO - European Society for Medical Oncology; ACS - American Cancer Society; USPSTF - 
US Preventive Services Task Forces 
 
 The diagnosis of BrC comprises clinical examination and confirmation by 
histopathological analysis (2). An image-guided core needle biopsy is currently 
recommended for breast lesions biopsy (2). Nevertheless, a fine-needle aspiration (FNA) 
can be performed when a core needle biopsy cannot be obtained (2). However, although 
the latter is sufficient to proceed with a definitive diagnosis, it cannot distinguish invasive 
from non-invasive lesions and the hormone receptor status cannot be evaluated (6). Thus, 
when possible, a core needle biopsy is the most suitable diagnostic technique since it is 
more cost-effective and an adequate amount of tissue for hormone receptors status 
evaluation can be collected (6). FNA or core needle biopsy is recommended in suspicious 
lymph nodes (2). 
 
HISTOLOGICAL SUBTYPES 
 Breast tumors can be divided in invasive and in situ carcinomas: invasive 
carcinomas comprise breast tissue cells’ abnormal proliferation that invades through the 
duct wall into stroma, whereas in situ carcinomas are non-invasive lesions defined by the 
proliferation of epithelial cells confined to breast ducts or lobules (25). In situ lesions can be 
ductal carcinoma in situ (DCIS) or lobular carcinoma in situ (LCIS), depending on 
cytoarchitectural features (26). Invasive ductal carcinoma (also known as ductal carcinoma 
NST or carcinoma of no special type) accounts for 70-80% of all breast tumors and 
comprises a heterogeneous group of tumors that do not display features classified as a 
specific histological type (25). Invasive lobular carcinoma is present in 5-15% of all BrC 
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patients and is considered special subtypes carcinomas (SSC), which also includes 
mucinous carcinoma, medullary carcinoma and invasive papillary carcinoma (25). A tumor 
presenting 10% to 49% of non-specialized pattern and a SSC is classified as a mixed type 
carcinoma (25). 
 
STAGING  
 After diagnosis, the stage of each BrC patient is determined in order to evaluate the 
disease extension and to define the best treatment. The TNM system of American Joint 
Committee on Cancer (AJCC)/ Union for International Cancer Control (UICC) is the most 
accepted and widely used for BrC staging (27). This system comprises tumor size and 
extension (T), regional lymph node status (N) and presence of distant metastasis (M) 
(Appendix I, Table 1) (27). Different combinations of T, N and M originate 5 stages (0, I, II, 
III and IV), used to stratify BrC patients and to predict prognosis and treatment (Appendix I, 
Table 2) (25). Staging can be clinically or pathologically determined. Clinical staging is 
based in physical examination and imaging studies and is mainly useful in a neoadjuvant 
context, whereas pathological staging includes a combination of clinical data and 
pathological examination for BrC staging (Appendix I, Table 1) (27).  
 
PROGNOSIS FACTORS  
 In addition to the staging, several biomarkers are used to predict the patient’s 
response to therapy and prognosis. The histological grade is attributed to each tumor 
according to the Nottingham combined system, and a high histological grade is associated 
with poorly differentiated tumors and worse prognosis (25). 
 The estrogen receptor (ER) is a nuclear transcription factor that stimulates breast 
normal cells growth by the binding of estrogen. This process is particularly important in 
cancer development since it induces tumor growth. Seventy-five % of BrC tumors are ER-
positive, being well-differentiated, less aggressive, and associated with a better prognosis 
(28). ER positivity is a predictor of the response to hormonal therapies (HT) with tamoxifen 
and aromatase inhibitors. Tamoxifen binds to the ER in BrC cells and inhibits the signaling 
pathways that would lead to cell growth (28). Moreover, about 65-75% of the breast tumors 
are progesterone receptor (PR) positive and its function is usually related to ER signaling 
activation (25, 28). Accordingly, PR-positive tumors are frequently ER-positive, and 
associate with a therapy response rate of 75-85%. On the contrary, ER- and PR- tumors are 
frequently grade 3, often recur and do not respond to HT (25). 
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 Erb-B2 receptor tyrosine kinase 2 (ERBB2) [or human epidermal growth factor 
receptor 2 (HER2)] is a growth factor receptor expressed by breast epithelial cells 
membrane (25). Currently, it is evaluated by immunohistochemistry (IHC) and/or 
fluorescence in situ hybridization (FISH), being overexpressed in 15% of all BrC cases (28). 
Therapies targeting ERBB2 such as transtazumab and lapatinib are currently available for 
BrC patients, improving the patient’s outcome (28). 
 Gene expression profiles have been emerging to assist in adjuvant treatment 
decision (27). Oncotype DX® (21‑gene panel), MammaPrint® (70‑gene panel) and PAM50 
(Prosigna) (50‑gene panel) are different gene expression profiles that allow for BrC tumors’ 
classification and prognosis evaluation (29). Nonetheless, its usefulness in clinical practice 
is limited and therefore their implementation remains restricted, since the evidence of their 
using in clinical practice is limited and associated with high costs (29).  
 
MOLECULAR SUBTYPES  
 BrC is a heterogeneous disease and efforts in better patients’ stratification led to 
BrC tumors classification into molecular subtypes based on gene expression patterns (6). 
Different combinations of ER, PR and ERBB2 expression patterns allowed the definition of 
several molecular subtypes: luminal A, luminal B, ERBB2-enriched and basal-like (27). 
Luminal-like A and B tumors account for 70-80% of all BrC tumors. Luminal A presents high 
ER and PR expression levels, but low/reduced ERBB2 and Ki67 expression levels, whereas 
luminal B type is associated with high proliferation marker levels (Ki67) and/or ERBB2 
expression (Table 2) (2). Luminal A tumors present a low number of mutations and better 
prognosis than luminal B tumors (2). In contrast, ERBB2-enriched tumors are positive for 
ERBB2 expression, but not to hormone receptors (Table 2). This molecular subtype usually 
displays high mutation rate, is highly proliferative and associated with poor prognosis, albeit 
with several available targeted therapy options (30). Basal-like BrC tumors are defined as 
such because express basal-cells biomarkers and are triple-negative, i.e., do not express 
ER, PR and ERBB2 (31). Accordingly, basal-like tumors are often referred as triple-negative 
breast cancer (TNBC) tumors, though not all TNBC tumors express basal-cells biomarkers 
(32). The basal-like subtype is frequently associated with TP53 mutations and convey the 
worst prognosis among all molecular subtypes (32). 
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Table 2. BrC subtyping by IHC. Adapted from (2, 27). 
 Luminal A 
Luminal B 
(ERBB2-negative) 
Luminal B 
(ERBB2-positive) 
ERBB2 
overexpression 
Basal-like 
ER + + + - - 
PR + -* +/- - - 
ERBB2 - - + + - 
Ki67 - +* +/- +/- +/- 
* Either PR – or Ki67 +; “+” – high expression; “-“ – low expression; “+/-“ – any;  
Abbreviations: ER – Estrogen receptor; ERBB2 - Erb-B2 receptor tyrosine kinase 2; PR – Progesterone receptor 
 
TREATMENT 
 BrC treatment decision should be provided by a multidisciplinary team including a 
surgeon, medical oncologist, radiation oncologist, radiologist and pathologist (2). The 
treatment strategy must be discussed and explained to the patient (2). Surgery, 
radiotherapy (RT), chemotherapy, HT and target therapy are the main modalities for BrC 
treatment available (33). 
 Surgery is the first treatment used in operable BrC tumors (2). Sixty to 80% of 
operable tumors allow for a breast conservation surgery with negative margins, which is 
associated with better cosmetic outcomes and less morbidity (2). Mastectomy is indicated 
for BrC patients that prefer this type of treatment and that are not indicated for breast 
conservation surgery, as in multifocal tumors (Figure 2) (6). Nowadays, the assessment of 
node-metastasis in the sentinel lymph node is a standard procedure for treatment decision 
making, since axillary clearance is associated with lymphedema (2). 
 Adjuvant RT after surgery is strongly recommended by ESMO guidelines, 
associating with a recurrence risk reduction by 8-15% (Figure 2) (2). Adjuvant systemic 
treatment might be also used based on the patients’ comorbidities, preferences and risk of 
recurrence (2). BrC recurrence risk can be estimated by the tumor’s biological 
characteristics (2). Indeed, low-risk luminal tumors are indicated for adjuvant therapy with 
HT, whereas higher risk luminal tumors (luminal B ERRB2-positive) have indication for 
chemotherapy, HT and targeted therapy with transtuzumab (approved for node-positive 
disease and for node-negative  patients  with  tumors  greater  than  1  cm) (2). Furthermore, 
for luminal BrC, gene expression profiles such as Oncotype DX®, MammaPrint® and PAM50 
can be used for adjuvant treatment decisions (2). The molecular subtypes with poorer 
prognosis, i.e., ERBB2-enriched and TNBC tumors have indication for chemotherapy and 
targeted therapy in tumors ERBB2-positive. 
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 Moreover, neoadjuvant therapy is offered to BrC patients with locally advanced and 
bulky tumors that can be removed by surgery if downsized (33). Chemotherapy, HT and 
targeted therapy are the most commonly used neoadjuvant treatments (2). Metastatic BrC 
patients are usually treated in monotherapy with anthracycline or taxane chemotherapy-
based regimens (34). 
 
 
Figure 2. Early BrC treatment algorithm according to ESMO guidelines (2). Adapted from (2). Abbreviations: 
HT - Hormone therapy; RT - Radiotherapy 
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COLORECTAL CANCER 
 
RISK FACTORS  
 CRC development is associated with several environmental and genetic risk factors 
(6). A western-type diet with high fat levels and a sedentary lifestyle increases the CRC’s 
risk (6). Additionally, lifestyle habits such as smoking and alcohol consumption increase the 
risk of developing CRC in 1.11 (35) and 1.37 (for heavy drinking) (36), respectively. 
Furthermore, inflammatory bowel diseases history including ulcerative colitis and Crohn’s 
disease is a risk factor for CRC development. Indeed, the risk of CRC increases with the 
duration and degree of inflammation (37). Conversely, fruits, vegetables, calcium and 
prolonged nonsteroidal anti-inflammatory drugs (NSAIDS) consumption constitute CRC 
protective factors (6, 38). 
 Hereditary syndromes account for 5-10% of all CRC cases (39). Lynch syndrome is 
the most common hereditary nonpolyposis colorectal cancer (HNPCC) syndrome 
characterized by germline mutations at the mismatch repair (MMR) genes (MSH2, MLH1, 
MSH6, PMS2 and EPCAM) (40). MMR mutations usually result in microsatellite instability 
(MSI) (41). Its transmission is autosomal dominant and associated with a lifetime risk of 
developing CRC higher than 80% (40). Amsterdam and/or Bethesda criteria are useful to 
identify families that could carry Lynch syndrome (40). Families with Lynch syndrome are 
recommended to perform colonoscopy every 1-2 years (40). Hereditary polyposis 
syndromes such as familiar adenomatous polyposis (FAP) [Adenomatosis polyposis coli 
(APC) mutation] have 100% of penetrance and its most frequent clinical presentation is the 
presence of hundreds of polyps at young ages (42). MUTYH-associated polyposis, 
polymerase proofreading-associated polyposis, juvenile polyposis syndrome and Peutz-
Jeghers syndrome are two other syndromes associated with high risk of CRC development 
(42). 
 
SCREENING AND DIAGNOSIS 
 CRC screening has been shown to decrease the CRC incidence and mortality, 
mainly due to the implementation of colonoscopy and fecal occult blood test (FOBT) (6). 
Colonoscopy allows the visualization of the entire colon, the removal of precancerous 
lesions and the biopsy of a lesion present at the time of the exam (43). The evidence of 
colonoscopy screening arises from observational and indirect data, since there are no 
randomized clinical trials to demonstrate the effects of colonoscopy in CRC incidence and 
mortality. In a prospective study, the estimated reduction in CRC mortality in patients with 
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polyps removed by colonoscopy was higher than 50% (Table 3) (44). Additionally, a 
randomized controlled trial showed that a one-time screen with flexible sigmoidoscopy 
(visualization of sigmoid colon and rectum) reduced the CRC incidence by 21% and 
mortality by 31% (Table 3) (45). Since colonoscopy examines all the colon, better results 
can be expected from colonoscopy screening. As a result, several screening guidelines 
recommend a colonoscopy examination at the age of 50 and, if this is negative, every 10 
years (39, 46). Nevertheless, colonoscopy screening involves bowel preparation, an 
invasive procedure and a risk of bleeding and bowel perforation (6). Furthermore, about 
22% of all adenomas are missed in a colonoscopy examination, particularly in the right 
colon, which increases the risk of interval cancers (tumors occurring more than 6 months 
after a colonoscopy and prior to the next screening exam) (47). 
 FOBT is widely recommended for annual CRC screening due to its low 
invasiveness, cost and acceptable performance as a screening test (39). Two or three 
screenings with guaiac-based faecal occult blood testing (gFOBT), based on peroxidase-
like activity of heme (6), reduced CRC mortality in 15% (Table 3) (48). However, blood 
presence in stool can result from dietary factors or other bowel conditions (43). Feacal 
immunochemical test (FIT) based on the use of antibodies for human globin increases the 
specificity of FOBT (43). Its performance in CRC detection is similar to guaiac-based FOBT, 
although it has been reported that the compliance for a FIT screening is higher, because no 
dietary restrictions are needed (49). Nonetheless, these tests have limited performance in 
detecting precancerous lesions as early lesions bleeding is uncommon (50). Multitarget 
DNA stool tests such as Cologuard®, that allies FOBT with KRAS mutation and BMP3 and 
NDGR4 methylation (51) and plasma-based biomarkers were proposed as novel screening 
modalities for CRC screening (52). 
 
Table 3. Test performance of screening tests currently used for CRC screening. Adapted from (53). 
 gFOBT FIT 
Flexible 
sigmoidoscopy 
Colonoscopy 
Sensitivity % 13-50 79 90-92 92-99 
Reduction in CRC 
incidence % 
No Unknown 21 69 
Reduction in CRC 
mortality % 
14-16 22 31 68 
Abbreviations: CRC – Colorectal Cancer; FIT - Feacal immunochemical test; gFOBT - Guaiac-based faecal 
occult blood testing  
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 CRC symptoms include gastrointestinal bleeding, iron deficiency or anemia, bowel 
habits change, weight and appetite loss, abdominal pain and obstructive symptoms (39, 
54). Acute obstruction, abdominal distention and constipation are more frequent in left colon 
tumors (6). A clinical evaluation with a physical examination, FOBT, and endoscopic 
procedure (sigmoidoscopy or colonoscopy) should be performed (39). In addition, a 
suspicion of metastatic disease should be confirmed by computed tomography (CT), MRI 
or positron emission tomography (PET) (54). The carcinoembryogenic antigen (CEA) at the 
diagnosis should also be evaluated, since its levels might be used as disease monitor 
biomarker after treatment/ follow-up (39). 
 
MOLECULAR PATHWAYS   
 The majority of CRCs develop from early neoplastic lesions due to the loss of 
genomic and epigenomic stability (55). CRC development may result from several 
molecular pathways: chromosomal instability (CIN), MSI and cytosine-phosphate-guanine 
(CpG) island methylator phenotype (CIMP) (55). CIN accounts for 85% of the molecular 
pathway of sporadic CRCs and is characterized by a loss of tumor suppressor genes and 
a gain of oncogenes copy number (56). APC mutations is one of the initial key mutations 
involved in both sporadic CRC with CIN genotype and FAP syndrome (56). Its inactivation 
leads to an active WnT signaling, which stimulates cellular proliferation, migration and 
adhesion (56). CIN leads to further mutations, as is the case of KRAS, an oncogene that 
leads to a permanently active cellular stage and continuous growth (56, 57). This molecular 
pathway is the most common in the transition from adenoma to adenocarcinoma, beginning 
with the formation of a small adenomatous polyp that eventually evolves to a larger polyp 
with dysplasia and, ultimately, adenocarcinoma (58).  
 The MSI pathway occurs in 15% of the sporadic CRC and in more than 9% of 
HNPCC syndromes (57). MSI arises from the inactivation of MMR (system that repairs 
mismatched nucleotides in DNA replication), increasing the mutation rate of other cancer 
related genes in the colorectal mucosa (56). MMR’s inactivation in sporadic cancers often 
arises from MLH1 promoter epigenetic silencing, whereas MLH1 and MSH2 mutations are 
more common in patients with Lynch syndrome (57). Moreover, MSI CRC cancers usually 
present BRAF mutation V600E, involved with cellular responses to growth signals (57). 
About 15-20% of serrated adenocarcinomas have origin in sessile serrated polyps, which 
usually also display high levels of MSI (58). 
 CIMP is characterized by aberrant promoters’ hypermethylation of tumor suppressor 
genes. It can be found in 20-30% of CRC cases (57) and CIMP-high patients display a high 
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rate of BRAF mutations. In addition to being associated with MSI, sessile serrated polyps 
present also high frequency of CIMP and are usually right-sided lesions (58). 
 
HISTOPATHOLOGY AND PRECURSOR LESIONS 
 About 90% of CRC tumors are classified as adenocarcinomas, which originate in 
epithelial cells of the colorectal mucosa (59, 60). Their grading is based on the percentage 
of glandular formation, i.e., low-grade tumors are well or moderately differentiated tumors, 
whereas poorly differentiated tumors are classified as high-grade (59). Other histological 
variants include mucinous adenocarcinoma, with >50% of the lesion being constituted by 
extracellular mucin, and signet ring cell carcinoma, with prominent intracytoplasmatic mucin 
in more than 50% of tumor cells (59, 60). Other rare types of carcinomas comprise 
neuroendocrine, squamous cell, adenosquamous, and undifferentiated carcinomas (59). 
The majority of CRC tumors arise from precursor lesions such as adenomas (60). They can 
be classified as tubular, tubulovillous and villous. Adenomas with more than 1 cm in size, a 
villous pattern, and containing high-grade dysplasia are classified as advanced adenomas 
and are frequently malignant (60).  
 
STAGING  
 The TNM system classification of AJCC/UICC is currently used for CRC staging 
(27). In CRC staging T accounts for primary tumor invasiveness: T1 involves the 
submucosa, T2 the invasion of muscularis propria, T3 the invasion of pericolorectal tissues 
through muscularis propria and T4 the invasion of visceral peritoneum or adhesion to 
adjacent organs or structures (Figure 3) (Appendix II, Table 3) (27). Regarding regional 
node status (N), at least 12 lymphatic nodes must be collected for correct staging. The N 
stage is attributed according to the number of nodes with metastasis (Appendix II, Table 3) 
(27). As staged earlier, the M parameter accounts for distant metastasis and M1 patients 
are classified as stage IV (Appendix II, Table 4) (27).  
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Figure 3. Definition of primary tumor (T) according to the 8th edition of AJCC Cancer Staging Manual for CRC 
staging. Nunes SP unpublished  
 
TREATMENT  
 According to ESMO guidelines, the treatment of colon and rectum cancers should 
be decided by a multidisciplinary team according to the patient’s preferences and co-
morbidities (39, 54, 61). Regarding colon cancer stage 0, a local excision during an 
endoscopic exam should be carried out when possible. In localized disease, surgical 
resection is usually the first-line of treatment (Figure 4) (39). For high-risk stage II patients 
(lymph node sampling <12, poorly differentiated tumor, perineural invasion, presence of 
obstruction or perforation and pT4 stage) and stage III, the surgical resection is followed by 
adjuvant chemotherapy (Figure 4) (39). The recommendations for rectal cancer treatment 
include surgery or local RT for very early disease and chemoradiotherapy followed by 
surgery when possible for stages II and III (Figure 4) (61). In metastatic CRC, surgery is an 
option for resectable metastatic disease or for those that became resectable after tumor 
reduction by chemotherapy (54). For unresectable metastatic CRC, chemotherapy 
associated with bevacizumab [monoclonal antibody against vascular endothelial growth 
factor (VEGF)] is usually the first line of treatment (Figure 4) (54). Other biological agents 
such as aflibercept, a recombinant fusion protein that blocks VEGF, and anti-epidermal 
growth factor receptor (EGFR) for patients without RAS mutations are second-line options 
for metastatic CRC treatment (54). 
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Figure 4. Simplified algorithm of CRC treatment according to ESMO guidelines (54, 61, 62). Adapted from (63). 
*For rectal cancer treatment. 
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LUNG CANCER 
 
RISK FACTORS 
 Several risk factors are associated with LC development including cigarette 
smoking, genetic factors, asbestos and silica fibers, and exposure to ionizing radiation (6). 
Smoking is the most well-established risk factor of LC, since about 85% of LC cases arise 
from cigarette smoking (64). Smokers display a 16-fold increased risk of developing LC, 
which increases exponentially with the duration of smoking exposure (64). The tobacco 
smoke contains several carcinogens that induce malignant alterations in respiratory 
epithelial cells such as benzo(a)pyrene, nitrates and 4-(methylnitrosamino)-1-(13-pyridyl-1-
butanone) (NNK) (6). Furthermore, smoking cessation decreases the risk of LC 
development, although it is never comparable to a never smoker (6). Second-hand smoking 
also constitutes a risk factor for LC, being associated with a 25% risk of LC development 
(65). Indeed, smoke carcinogens metabolites are present in body fluids of non-smokers 
exposed to tobacco smoke (65, 66). 
 Although smoking is the main risk factor, only 15% of smokers develop LC, 
indicating that other risk factors have also an important role in LC development (6). Family 
history of LC increases by 2-3 fold the risk of LC (6). Additionally, the risk of LC is higher in 
smokers with Li-Fraumeni syndrome (67).  
 Occupational and environmental exposure to asbestos and silica fibers accounts for 
15% of LC cases (65), having a synergetic effect with smoking (65). Likewise, exposure to 
ionizing radiation such as radon and air pollution also increases the LC risk (65). 
 
SCREENING AND DIAGNOSIS  
 LC is the main cause of death by cancer in women in developed regions (1), since 
about 75% of the lung cancers cases are diagnosed at advanced stages (68). Thus, the 
main goal of LC screening is to detect it in curative early stages, leading to a reduction in 
LC-related mortality (69).   
 Several studies determined the feasibility of low-dose computed tomography 
(LDCT) for LC screening (70-72). The National Lung Screening Trial (NLST) compared the 
performance of LDCT with chest X-ray in LC screening (73). A 20% decrease in LC-related 
mortality for the LDCT group was found, with a higher percentage of stage IA 
adenocarcinomas detection in the LDCT group (73). However, of the 39% positive test 
results in NLST, 96.4% were false-positive (73), which resulted in psychological stress and 
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unnecessary exams (74). Additionally, LDCT screening displays a high rate of 
overdiagnosis (estimated 18.5%), exposure to radiation, high costs (74), and similar clinical 
trials did not found a significant reduction in LC mortality with LDCT (75-77). Most recently 
the Dutch-Belgian Lung Cancer Screening Trial (NELSON) randomized 15 822 current or 
former smokers into two groups: the LDCT screening group or the control group (not offered 
any type of screening). The NELSON trial showed a lower false positive results rate and a 
higher percentage of stage I LCs detection in comparison with the NLST (78). 
Consequently, LC screening with LDCT is not widely implemented, however an annually 
LC screening with LDCT in high-risk asymptomatic adults (30 pack-year smoking history, 
currently smokers or have quit in less than 15 years) with ages above 55 years old is 
recommended (79, 80). 
 Patients with LC can present persistent cough, shortness of breath, chest pain and 
hemoptysis (6). Advanced LC may be associated with dyspnea, anorexia, weight loss and 
symptoms related to the metastasized organ including abdominal pain when liver, adrenal 
glands or pancreas are affected (81). A clinical evaluation in combination with imaging 
exams (chest X-ray, CT scan and PET scan) and laboratory tests should be performed for 
tumor extension assessment (Figure 5) (82). Moreover, a tumor’s sample should be 
collected either by bronchoscopy, sputum cytology or fine-needle aspiration, depending on 
the tumor’s location (Figure 5) (82). 
 
 
Figure 5. Scheme of the diagnostic procedures depending on the lesion location in lung. Adapted from (6) 
Abbreviations: CT - Computed tomography; PET - Positron emission tomography. 
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HISTOLOGICAL SUBTYPES 
 LC histological major subtypes comprise the non-small cell lung cancer (NSCLC) 
(adenocarcinoma, squamous cell carcinoma and large-cell carcinoma), that accounts for 
80% of all LC cases, and the small cell lung cancer (SCLC) (81). Adenocarcinoma has 
emerged as the main LC subtype (>40% of LC cases) due cigarettes’ manufacturing 
modifications (81). Specifically, the introduction filters and new blends lead to a puff volume 
increase, which caused a shift  from squamous cell carcinoma and SCLC (central deposition 
of the smoke) to adenocarcinoma (more peripheral deposition of tobacco smoke) (81).  LC 
adenocarcinoma usually arises from peripheral airways and displays glandular 
differentiation with mucin production or pneumocyte marker expression (81). The prognosis 
is strongly related with the stage, however never-smokers and female patients usually 
display a better prognosis (81). Squamous cell carcinoma that histologically exhibits 
keratinization and/or intercellular bridges, constitutes the second most frequent LC subtype 
(81). These tumors usually have a superficial growth and spread to adjacent structures (81). 
 SCLC is the subtype most associated with smoking and accounts for 13% of all LC 
cases (81). It arises in a central location with a rapid growing and metastization, 
representing the most aggressive LC subtype (6). Histologically, SCLC presents densely 
packed small tumor cells with a diffuse growth pattern and a high degree of mitosis (81). As 
expected, SCLC displays a low 2-year survival rate (about 10%) and the worst prognosis of 
all LC subtypes (81). Carcinoid tumors are also neuroendocrine tumors that represent 1% 
of all LC tumors (83). They frequently arise from central airways and can be divided in 
carcinoid typical or atypical, depending on the grade (typical, low-grade and atypical, 
intermediate-grade) (83). Atypical carcinoid has a poorer prognosis than typical carcinoid, 
the latter presenting a 5-year survival rate of 90% (81). 
 
STAGING  
 As for BrC and CRC, the TNM system is used for LC staging determined by clinical 
or pathological evaluations (27). The clinical staging uses information before the treatment, 
whereas pathological staging is assessed after surgery in order to decide the adjuvant 
treatment (27). The parameter T accounts for the tumor size and invasion. Furthermore, the 
regional node status N assesses the nodal chains affected and M the presence of distant 
metastasis (Appendix III) (27).  
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TREATMENT 
 The treatment of LC includes surgery, chemotherapy, RT and target agents in the 
presence of EGFR or anaplastic lymphoma kinase (ALK) mutations (82, 84). For stages I 
and II, surgery with complete resection of the lesion and, at least, six lymphatic nodes is the 
first line treatment recommended (82). Adjuvant chemotherapy is recommended for 
resected NSCLC stages II and III and for all stages of SCLC after surgery (82, 84). 
Postoperative RT is recommended in patients with the resection margins positive and with 
lymph node metastasis (82). Stereotactic RT is preferred in NSCLC stage I patients with 
comorbidities or that cannot be operated for other reasons (82). In advanced LC, surgery 
followed by adjuvant chemotherapy or chemoradiotherapy should be applied in resectable 
tumors, whereas chemoradiotherapy is the first recommended line of treatment for 
unresectable LC (induction chemotherapy followed by RT) (82). Chemotherapy is used as 
the first treatment for metastatic SCLC and NSCLC without mutations on EGFR, proto-
oncogene tyrosine-protein kinase ROS (ROS1) or ALK genes, (85), whereas target therapy 
is used for NSCLC with EGFR, ROS1 or ALK mutations (85). Recently, immunotherapy with 
programmed death-ligand 1 (PD-L1) inhibitors was approved for metastatic NSCLC patients 
(86). 
 Several mutations in proto-oncogenes were identified as potential targets for LC 
therapy. EGFR is a transmembrane tyrosine kinase that leads to cell proliferation when 
activated. In the presence of EGFR mutations, the signaling pathway is constitutively 
activated (6). EGFR mutations are more frequent in never and light-smokers and occur in 
17% of adenocarcinomas (87). The presence of EGFR mutations is the main predictor of 
response to EGFR-target therapies such as gefitinib, erlotinib and afatinib (85). 
Nonetheless, 50% of LC patients have disease progression due to EGFR acquired 
mutations and a second-line of EGFR inhibitors can be offered (85). In adenocarcinomas, 
ALK and ROS1 rearrangements predict response to crizotinib, a targeted agent that blocks 
the signaling by tyrosine kinases (85, 88). 
 
 Thus, detection of cancer early stages increases the likelihood of a successful 
treatment, leading to a potential cure and low-rate of recurrences. Although current 
screening strategies are beneficial, they have significant limitations, comprising risk of 
overdiagnosis/overtreatment, invasiveness and high cost, entailing low compliance and 
suboptimal specificity, requiring further testing and increasing suspects’ anxiety (19, 50). 
Hence, development of better pre-screening methods, which might perfect selection to 
invasive/costly screening tests is mandatory.  
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EPIGENETICS  
  
 Epigenetics, firstly mentioned by C. Waddington in 1942, can be defined as heritable 
alterations in gene expression without changing the DNA sequence (89). The epigenetic 
regulation is essential to normal cell mechanisms, namely embryonic development, 
imprinting and tissue differentiation (90). The main epigenetic mechanisms include DNA 
methylation, histone post-translational modification, histone variants and chromatin 
remodeling complexes (Figure 6) (91). The study of the epigenome increased the 
understanding of cancer, since deregulation of epigenetic mechanisms are implicated in 
cancer development (89, 90).  
 
Figure 6. Four main epigenetic mechanisms involved in gene expression regulation. DNA methylation consists 
in an addition of a methyl group in cytosine present in a cytosine-phosphate-guanine (CpG) dinucleotide. 
Histone post-translational modifications refer to alterations in histone tails such as methylation, acetylation, 
phosphorylation and ubiquitination that regulate gene expression. Histone variants differ few amino acids from 
canonical histones and regulate chromatin remodeling and histone post-translational modifications. Chromatin 
remodeling complexes regulate the nucleosome structure by removing, relocate and shifting histones. (Kindly 
provided by Lameirinhas A. unpublished) 
 
DNA METHYLATION  
 DNA methylation is the most investigated epigenetic alteration that consists in a 
covalent addition of a methyl group at the 5-position carbon of cytosine present in a CpG 
dinucleotide (91). In normal mammalian cells, CpG dinucleotides are usually methylated. 
Nevertheless, unmethylated CpGs are frequently found in CpG islands (sequences with 
200-500 bases with more than 50% of CpG dinucleotides in content) (90). About 50% of 
CpG islands are present in gene’s promoter regions, and their methylation is associated 
with transcription repression (90). On the other hand, methylation can also occur in the gene 
body that, conversely, is associated with transcriptional activation (90). DNA methylation 
Histone variants
Histone post-translational 
modifications
DNA methylation
Chromatin remodeling 
complexes
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can also be found in CpG island shores (2 kb areas upstream of a CpG island with CpG 
dinucleotides, but in lower frequency than CpG islands). CpG island shores’ methylation is 
also associated with transcriptional repression and tend to be tissue-specific (90). DNA 
methylation can induce the binding of transcriptional repressors or impede the binding of 
transcriptional factors, resulting in gene transcription inhibition (90). In fact, a family of 
methyl-CpG-binding proteins (MBPs) intervenes in the tumor suppressor genes’ silencing 
by binding to the methylation CpGs and recruiting histone modification enzymes to establish 
histone post-translation modifications to further sustain transcriptional repression (92). 
 DNA methylation is catalyzed by DNA methyltransferases (DNMTs), namely 
DNMT3a and DNMT3b that catalyze de novo DNA methylation during embryonic 
development, establishing tissue-specific DNA methylation, and DNMT1 that preferably 
maintains the DNA methylation patterns already existing (90). X chromosome inactivation 
in female mammals, silencing of repetitive centromeric sequences and transposons along 
with genomic imprinting are cells’ main DNA methylation mechanisms in order to maintain 
genomic stability (90). DNA demethylation is performed by ten-eleven methylcytosine 
dioxygenase (TET) enzymes, that catalyze the conversion of 5-methylcytosine to 5-
hydroxymethylated cytosine, maintaining CpG islands’ unmethylated state (92).   
 Generally, global hypomethylation is observed in cancer epigenome, which 
contributes to overexpression of proto-oncogenes, mutation rates increase and loss of 
imprinting, resulting in genomic instability (93). Indeed, a decrease from 80% to 40-60% in 
methylation levels from normal cells to cancer cells is observed (93). Simultaneously the 
promoter’s hypermethylation at 5’ regions of tumor suppressor genes is also a frequent 
event in cancer cells (91). This alteration results in tumor suppressor genes’ inactivation, 
namely genes that inhibit invasion, metastasis and angiogenesis, and DNA repair genes. 
Typically, 5-10% of CpG island promoters are methylated in cancer (93).  
 Importantly, cancer-related genes methylation has been proposed as a potential 
biomarker for cancer detection and monitoring (94) due to several features: (i) it is a stable 
alteration; (ii) it is frequent and arises early in cancer development; (iii) its detection can be 
easily performed with quick and reliable techniques as sodium-bisulfite modification and 
quantitative methylation-specific PCR (qMSP) (iv) it can be detected in several biological 
samples including formalin-fixed paraffin-embedded tissues and several body fluids 
(sputum, serum/plasma, urine, stool) (94, 95). Indeed, the detection of DNA methylation in 
serum/plasma has shown to be promising in several cancers detection using a minimally-
invasive strategy (95). 
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LIQUID BIOSPIES  
 As earlier mentioned, tissue biopsy remains the standard method for cancer 
diagnosis. Nevertheless, it has been associated with several disadvantages: it may not 
represent the tumor heterogeneity and it does not allow to assess the treatment efficacy 
and detection of early recurrences or residual disease (96, 97). Therefore, a minimally-
invasive method that allows cancer detection and diagnosis in an early stage and patients 
follow-up is essential. Recently, the concept of liquid biopsy has emerged using biomarker 
analyses of blood.  Circulating cell-free tumor DNA (ccfDNA), circulating tumor cells (CTCs), 
circulating cell-free RNA and exosomes are the main forms of liquid biopsy described so far 
(98, 99).  
 CcfDNA was firstly reported in 1948 in blood of healthy donors (100) and after in 
cancer patients (101). CcfDNA fragments can be 70-200 base-pairs long in healthy controls, 
while ccfDNA in tumor patients can range from 150 to 1000 base-pairs, representing 0.01-
50% of all ccfDNA (99). The concentration of ccfDNA in blood also varies between healthy 
controls (0-100 ng/mL) and cancer patients (0-1000 ng/mL) (102). CcfDNA has a short half-
life ranging from 15 minutes to hours, being removed by the liver or kidney (102). Several 
studies showed that tumor ccfDNA can have various origins: (i) released from living tumor 
cells (103); (ii) apoptotic or necrotic tumor cells (104); (iii) CTCs (105) (Figure 7).  
 
Figure 7. CcfDNA liquid biopsy. Tumor DNA can have several origins, namely living tumor cells, apoptotic or 
necrotic tumor cells and circulating tumor cells (CTCs). Blood can be collected, the ccfDNA can be extracted 
from serum/plasma and analyzed in a context of a liquid biopsy. Nunes SP unpublished. 
Living tumor cells Necroting tumor cellsApoptotic tumor cells Circulating tumor cells
Centrifugation
Liquid biopsy
Sources of cell tumor DNA
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 It has been shown that ccfDNA contains alterations present in the tumor itself, 
namely mutations (106) and methylation alterations (107). The detection of  tumor-specific 
DNA methylation in ccfDNA constitutes a promising approach for cancer detection and 
monitoring, even in early lesions, which has been demonstrated by already approved tests 
such as Epi proColon® and Epi proLung® for CRC and LC detection in plasma, respectively 
(108, 109). Tumor ccfDNA for patient monitoring, namely a test for EGFR mutations, is 
already approved in NSCLCs liquid biopsies for disease monitoring and treatment response 
prediction (110).  
 
DNA METHYLATION-BASED BIOMARKERS 
 Several methylated genes have been proposed as tumor biomarkers for BrC, CRC 
and LC detection. Nevertheless, the sensitivity for cancer detection of one methylated gene 
in ccfDNA is limited, hence several studies attempted to assemble gene-methylation panels 
to increase the test sensitivity (111-114).  
 APC and Ras association domain family 1 isoform A (RASSF1A) are widely 
mentioned in several panels for BrC, CRC and LC detection (111, 115, 116) (Table 4, Table 
5, Table 6). APC, as a tumor suppressor gene, has a crucial role in Wnt signaling pathway, 
since its silencing by mutation or hypermethylation leads to an accumulation of β-catenin 
with consequent activation of Wnt signaling pathway (117). In addition, APC has been 
implicated in DNA repair, cytoskeleton regulation and apoptosis (117). RASSF1A is a tumor 
suppressor gene involved in apoptosis, cell-cycle progression and cell adhesion (118). 
Although APC and RASSF1A individually display a low sensitivity, their specificity for BrC 
detection is higher than 95% (111).  
 Furthermore, retinoic acid receptor beta 2 (RARβ2) is commonly hypermethylated 
in cancer patients and mentioned in panels for cancer detection (111, 119). Its main function 
is to regulate the epithelial growth by inducing growth inhibition and apoptosis induction in 
the presence of retinoic acid (120). RARβ2 promoter’s hypermethylation can be found in 
40% of LC patients and BrC cell lines (120, 121). Additionally, a four-gene panel with 
RARβ2, p16INK4a, 6-methylguanine DNA methyltransferase (MGMT), and APC 
hypermethylation detected 75% of CRC patients in stool samples (122).  
 Sex determining region Y box 17 (SOX17) has been recognized as an antagonist of 
Wnt signaling pathway (123). SOX17 promoter’s methylation is reported in ccfDNA and 
CTCs of BrC patients (124), CRC cell lines and tumors (125), and plasma of NSCLC 
patients (123). Indeed, a gene panel with CDO1, TAC1 and SOX17 displayed a sensitivity 
of 93% for LC detection (Table 6) (126).
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Abbreviations: MSP – methylation-specific PCR; qMSP – quantitative methylation-specific PCR
Breast Cancer 
Gene Panels Sensitivity (%) Specificity (%) Specimen type Methods References 
hMLH1 HOXD13 
P16 PCDHGB7 
RASSF1A SFN 
79 72 Serum qMSP (112) 
GSTP1 RARβ2 
RASSF1A 
22 93 Serum 
One-step 
 MSP 
(127) 
FKBP4 KIF1A MAL  
OGDHL VGF 
49 80 Plasma qMSP (128) 
APC DAP-kinase 
RASSF1A 
94 100 Serum MSP (129) 
DKK3 ITIH5  
RASSF1A 
67 69 Serum  qMSP (130) 
APC GSTP1  
RAR2 RASSF1A 
62 87 Plasma qMSP (111) 
ATM  
RASSF1A 
36 100 Plasma qMSP (131) 
ESR1 
14-3-3- 
81 55 Serum qMSP (132) 
APC ESR1  
RASSF1A 
53 84 Serum qMSP (133) 
DAPKI  
RASSF1A 
96 92 Serum MSP (134) 
RAR2 RASSF1A 
SCGB3A1 TWIST 
98 82 Serum qMSP (135) 
CDH1  
RASSF1A 
76 90 Serum MSP (136) 
Table 4. Previously published methylation panels for BrC detection in ccfDNA liquid biopsies. 
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 Secretoglobin family 3A member 1 (SCGB3A1) promoter’s hypermethylation is 
described as the main mechanism for its loss in BrC tumors and cells (137). Additionally, 
respective hypermethylation activates AKT signaling pathway in NSCLC cell lines (138). 
Moreover, SCGB3A1 has been associated with increased apoptosis and inhibition of cell 
cycle reentry, migration and invasion (137). SCGB3A1 hypermethylation was already 
mentioned as a potential biomarker for BrC detection in a four-gene panel with a sensitivity 
of 98% (Table 4) (135).  
 MGMT gene encodes a DNA repair protein that eliminates aberrant DNA bases 
exposed to alkylating and methylating agents (139). Methylation of MGMT promoter has 
been associated with several cancers including glioblastomas, CRC and BrC (139-141). 
 Fork-head box A1 (FOXA1) is a transcriptional factor involved in the embryonic 
development and tissue differentiation in prostate, breast, gastro-intestinal tract and lung 
(142). FOXA1 was shown to inhibit cell growth and to induce the expression of cell-cycle 
inhibitors including cyclin G2 (143). FOXA1 activity is related to ERα, since nearly 50% ER-
target genes are regulated by FOXA1 (144). Moreover, loss of FOXA1 or FOXA2 in 
pancreatic cancer cells is associated with epithelial-to-mesenchymal transition (145).  
 Septin 9 (SEPT9) belongs to a GTP binding protein family and is involved in normal 
cell mechanisms including division of cytoplasm, membrane reconstruction and cell 
polarization (146). In CRC, the expression of SEPT9 decreases with the progression from 
adenoma to invasive carcinoma (147). SEPT9 promoter’s methylation levels are currently 
used in several tests in ccfDNA extracted from plasma as a non-invasive biomarker for CRC 
detection (148, 149). As an example, Epi proColon® showed a 68% sensitivity and 80% 
specificity in plasma samples from CRC patients (Table 5) (149). 
 Short stature homeobox 2 (SHOX2) is a transcription factor involved in skeleton 
development and heart development (150). An association between SHOX2 promoter’s 
methylation and LC has been established, being explored as a possible LC biomarker (151, 
152). Indeed, recently a two-gene panel based on SHOX2 and PTGER4 methylation levels 
was approved in ccfDNA in Europe (109). The gene-panel detected 85% of the LC patients 
with a specificity of 50% (Table 6) (109).  
 Thus, the assessment of aberrant DNA methylation constitutes a valuable biomarker 
in ccfDNA extracted from plasma/serum, being a potential non-invasive strategy for early 
cancer detection. 
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Table 5. Previously published methylation panels for CRC detection in ccfDNA liquid biopsies. 
Abbreviations: MSP – methylation-specific PCR; qMSP- quantitative methylation-specific PCR  
Colorectal Cancer 
Gene Panels Sensitivity (%) Specificity (%) Specimen type Methods References 
SEPT9  
Epi proColon® 
68 80 Plasma qMSP (149) 
mBMP3 mNDRG4 
KRAS mutation  
Fecal hemoglobin 
Cologuard® 
92 87 Stool 
Multiplex  
QuARTS 
(51) 
mVimentin 
ColoSureTM 
41 95 Stool MSP (153) 
ALX4  
SEPT9 
71 95 Plasma qMSP (154) 
ALX4 SEPT9  
TMEFF2 
81 90 Plasma 
Multiplex 
qMSP 
(155) 
NPY PENK 
WIF1 
87 80 Serum 
Multiplex 
qMSP 
(113) 
APC MGMT 
 RASSF2A Wif-1 
87 92 Plasma MSP (115) 
BCAT1  
IKZF1 
77 92 Plasma 
Two-step 
qMSP 
(156) 
GATA5  
SFRP2   
81 55 Plasma MSP (157) 
EFHD1  
PPP1R3C 
90 64 Plasma MSP (158) 
HLTF  
hMLH1 
57 90 Serum qMSP (159) 
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aOnly stage I patients; Abbreviations: MSP – methylation-specific PCR; qMSP- quantitative methylation-specific PCR
Lung Cancer 
Gene Panels Sensitivity (%) Specificity (%) Specimen type Methods References 
PTGER4 SHOX2   
Epi proLung® 
85 50 Plasma 
Multiplex  
qMSP 
(109) 
p16INK4A 
CDH13 
39 100 Serum MSP (160) 
PRDM14  
RASSF1A 3OST2a 
83 76 Sputum qMSP (161) 
APC CDH13 DLEC1   
KLK10 RASSF1A 
84 74 Plasma MSP (116) 
CDKN2A/p16 DAPK 
GSTP1 RARβ2 
RASSF1A 
73 71 Serum MSP (119) 
APC CDH1 AIM1 
 MGMT RASSF1A 
75 73 Serum qMSP (114) 
AJAP1 CDO1  
HOXA9  MARCH11  
PTGDR UNCXa  
72 71 Serum qMSP (162) 
CDO1 TAC1 
 SOX17 
93 62 Plasma qMSP (126) 
DCC Kif1a  
NISCH RARβ2 
73 71 Plasma qMSP (163) 
DAPK MGMT  
p16/INK4a 
RARβ2 RASSF1A   
50 85 Serum MSP (164) 
CDH13 CDKN2A/p16 
FHIT RARβ2 
RASSF1A ZMYND10  
73 82 Plasma 
Two-step 
MSP 
(165) 
Table 6. Previously published methylation panels for LC detection in ccfDNA liquid biopsies. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
AIMS 
 
 
AIMS | 29 
 
 Despite efforts in early cancer detection, especially in BrC and CRC screening 
programs, BrC, CRC and LC remain the most incident and deadly cancers in women in 
developed regions. Hence, advances in detection of these 3 major cancers are needed, 
specifically in pre-screening methods, which might select patients to invasive/costly 
screening tests, avoiding overdiagnosis and unnecessary exams.  
 Because aberrant promoter methylation of cancer-related genes is frequent in the 
earliest steps of cancer development, DNA methylation has been proposed as a promising 
biomarker for cancer detection. Moreover, this is a stable alteration that can be detected in 
serum/plasma’s ccfDNA and easily quantified by methylation-specific PCR methods.  
 Thus, the main aim of this study was to develop a sensitive and specific methylation-
based test in ccfDNA liquid biopsies for simultaneous BrC, CRC and LC detection in women. 
For that: 
 Nine genes (APC, FOXA1, MGMT, RARβ2, RASSF1A, SCGB3A1, SEPT9, SHOX2 
and SOX17) identified as methylated in cancer samples were selected from 
literature and previous data from our group (166-168); 
 Promoter’s methylation levels of 9 genes were assessed by multiplex qMSP in 
ccfDNA extracted from plasma samples from female cancer patients (BrC, CRC 
and LC) and asymptomatic controls (AC); 
 The association between the gene methylation levels and clinicopathological 
parameters was evaluated; 
 A gene-panel with the best combination of sensitivity and specificity for cancer 
detection (“PanCancer” panel) was determined; 
 A gene-panel suitable to discriminate the 3 cancer types (“CancerType” panel) was 
identified.  
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CLINICAL SAMPLES 
PATIENTS AND SAMPLES COLLECTION 
 Blood samples were collected from female patients primarily diagnosed with BrC, 
CRC and LC at the time of diagnosis prior to any treatment from 2015 to 2018 at the 
Portuguese Oncology Institute of Porto, Portugal. Additionally, for control purposes, blood 
samples from female healthy donors with ages over 45 years old at the Portuguese 
Oncology of Porto were collected between 2016 and 2018 (Table 7). Relevant clinical data 
was collected from clinical records and displayed in a data base for analysis purposes.  
 This study was approved by the institutional review board (Comissão de Ética para 
a Saúde – CES 120/2015) of Portuguese Oncology Institute of Porto, Portugal. All patients 
and healthy donors enrolled in this study provided written informed consent, in accordance 
with the Declaration of Helsinki ethical principles. 
 
Table 7. Number of plasma samples of the BrC, CRC, LC patients and ACs. 
Type Number of plasma samples 
BrC 108 
CRC 72 
LC 73 
AC  103 
 
 
SAMPLES PROCESSING  
 Blood samples were collected into two or three EDTA tubes from each individual 
patient or healthy donor and was centrifuged at 2,000 rpm for 10 min. at 4°C. Plasma was 
collected and immediately frozen at -80°C. 
 
CELL-FREE DNA EXTRACTION  
The ccfDNA was extracted from ~3 mL of plasma using QIAamp MinElute ccfDNA 
(Qiagen, Germany), according to manufacturers’ recommendations. Firstly, 60 μL of 
magnetic bead suspension, 110 μL of proteinase K, and 300 μL of bead binding buffer were 
added to the plasma in a 15 mL tube. After a 10 min. incubation period, the tubes were 
placed in a magnetic rack and the supernatant was discarded when the solution was clear. 
Then, 200 μL of bead elution buffer were added and the mixture was transferred to a bead 
elution tube and incubated for 5 min. with shaking at 300 rpm. The bead elution tube was 
placed in a 2 mL magnetic rack and the supernatant was transferred to a new tube. 300 μL 
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of buffer ACB were added to the samples and the mixture was briefly vortexed and 
centrifuged. Next, the samples were transferred into a QIAamp UCP MinElute column and 
centrifuged at 6,000 x g for 1 minute. The column was washed 2 times with 500 μL of buffer 
ACW2, followed by a centrifugation at 14,000 rpm for 3 min.. Subsequently, the QIAamp 
UCP MinElute column was transferred to a 1.5 mL elution tube and the samples were 
incubated at 56ºC for 3 min. with the lid open. Ultimately, ccfDNA was eluted in 20 μL of 
sterile distilled water, incubated for 2 min. and then centrifuged at 14,000 rpm for 1 min.. All 
the steps were performed at room temperature. The extracted ccfDNA was stored at -20°C 
until further use. 
 
SODIUM-BISULFITE MODIFICATION 
 
 Sodium-bisulfite modification constitutes a gold-standard technique for methylation 
studies (169). It is based on consecutive chemical reactions (sulphonation, desulphonation 
and deamination) that lead to the conversion of all unmethylated cytosine residues to uracil 
residues, whereas methylated cytosines remain 5-methylcytosines (170) (Figure 8). The 
converted DNA can be used to methylation studies with PCR and sequencing, since it is 
possible to design primers and probes specifically for the modified DNA sequence (169).  
 
Figure 8. Sodium-bisulfite modification of DNA. The unmethylated cytosines are converted to uracil, whereas 
methylated cytosines remain unchanged. Abbreviations: C – cytosine residue; mC – methylated cytosine 
residue; G – guanine residue; U – uracil residue; 5-mC – 5-methylcytosine. (Kindly provided by A. Lameirinhas 
unpublished) 
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 All ccfDNA samples were modified using EZ DNA Methylation-Gold™ Kit (Zymo 
Research, USA) according to the manufacturer’s instructions. The first step consisted in 
adding 130 μL of CT conversion reagent solution to 20 μL extracted ccfDNA of each sample. 
Next, each sample was incubated at 98ºC for 10 min. for DNA denaturation and at 64ºC for 
180 min. in Applied Biosystems Veriti 96-Well Thermal Cycler (Thermo Fisher Scientific, 
USA). After, the samples and 600 μL of M-Binding buffer were added to Zymo-SpinTM IC 
column and were incubated at room temperature for 10 min.. The columns were centrifuged 
at 10,000 rpm for 30 seconds. After the addition of 100 μL of M-Wash buffer and further 
centrifugation, 200 μL of M-Desulphonation buffer were added to the column followed by a 
20 min. incubation and a 10,000 rpm centrifugation for 30 seconds. Then, the column was 
washed two times with 200 μL of M-Wash buffer and two centrifugations at 10,000 rpm for 
30 seconds. The columns were placed in a 1.5 mL safe-lock tube where 10 μL of sterile 
distilled water were added to elute the bisulfite-converted DNA. After a 5 min. incubation at 
room temperature, the columns were centrifuged at 12,000 rpm for 30 seconds. This 
process was repeated twice. One μg of CpGenome™ Universal Methylated DNA (Millipore, 
USA) was modified using the protocol above mentioned and was eluted in 30 μL of sterile 
distilled water. The bisulfite-converted DNA was stored at -80°C until further use. 
WHOLE GENOME AMPLIFICATION  
 
 The ccfDNA is present in low quantity and quality in plasma/serum samples, and the 
sodium-bisulfite modification leads to further DNA degradation (171). The whole genome 
amplification (WGA) of bisulfite-converted DNA is a method that amplifies samples with low 
DNA quantity, yielding high DNA amounts for methylation analysis (172). A multiple 
displacement amplification (MDA) method was used for WGA in this study. MDA is based 
on an isothermal reaction using a DNA polymerase with exonuclease proofreading activity 
to decrease potential amplification biases (173). 
 WGA of sodium-bisulfite modified ccfDNA was carried out using the EpiTect Whole 
Bisulfitome Kit (Qiagen, Germany) according to the manufacturer’s recommendations. 
Briefly, 10 µL of modified DNA were mixed with 30 µL of EpiTect amplification master mix 
that contained 29 µL of EpiTect WBA reaction buffer and 1 µL REPLI-g Midi DNA 
polymerase. Then, the samples were incubated in Applied Biosystems Veriti 96-Well 
Thermal Cycler (Thermo Fisher Scientific, USA) at 28°C for 8 hours and 95°C for 5 min. for 
polymerase inactivation. The amplified DNA was diluted in 25 µL of sterile distilled water, in 
a final volume of 65 µL, and stored at -20°C until further use.  
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NUCLEIC ACID QUANTIFICATION 
 
 The DNA concentration was measured using the Qubit fluorometric method, in which 
a fluorescent dye binds specifically to a target, such as a double- or single-stranded DNA 
(174).  
 The extracted ccfDNA and amplified DNA were quantified using Qubit dsDNA HS 
Assay Kit (Invitrogen, California, USA), and the sodium-bisulfite converted DNA was 
quantified with Qubit ssDNA Assay Kit (Invitrogen, California, USA). Firstly, a working 
solution containing 199 µL of Qubit dsDNA HS Buffer/Qubit ssDNA Buffer and 1 µL of Qubit 
dsDNA HS Reagent/Qubit ssDNA Reagent per sample was prepared. Then, 199 µL of the 
working solution were added to 1 µL of the DNA sample. The DNA concentration was 
determined using Qubit 2 Fluorometer (Invitrogen, California, USA) following the 
manufacturers’ recommendations.  
MULTIPLEX QUANTITATIVE METHYLATION SPECIFIC PCR 
 
 The nine genes promoters’ methylation levels (APC, FOXA1, MGMT, RARβ2, 
RASSF1A, SCGB3A1, SEPT9, SHOX2 and SOX17) were assessed by multiplex qMSP. 
Primers and probes specifically designed to the modified gene sequence plus the 
fluorochromes and quenchers used for each probe are listed in Table 8. β–Actin was used 
as a reference gene to normalize the DNA quantity of each sample (167).  
 
Table 8. Primers and probes sequences with respective fluorochrome and quencher.  
Gene Sequences 
β-Actin 
Primers 
F – 5’ TGG TGA TGG AGG AGG TTT AGT AAG T 3’ 
R – 5’ ACC AAT AAA ACC TAC TCC TCC CTT AA 3’ 
Probe 
5’ Cy5 – ACC ACC ACC CAA CAC ACA ATA ACA AAC ACA 
– QSY 3’ 
APC 
Primers 
F – 5’ TGT GTT TTA TTG CGG AGT GC 3’ 
R – 5’ CAC ATA TCG ATC ACG TAC GC 3’ 
Probe 5’ VIC – CAATCGACGAACTCCCGAC – MGB 3’ 
FOXA1 
Primers 
F – 5’ CGA CGT TAA GAC GTT TAA GC 3’ 
R – 5’ CGC TCA ACG TAA ACA TCT TAC 3’ 
Probe 5’ FAM -ATA TAC GAA TAA AAC GAC TTA ACG – MGB 3’ 
MGMT Primers 
  F – 5’ TTT CGA CGT TCG TAG GTT TTC GC 3’ 
  R – 5’ GCA CTC TTC CGA AAA CGA AAC G 3’ 
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Probe 5’ VIC – TGC GTA TCG TTT GCG – MGB 3’ 
RARβ2 
Primers 
F – 5’ TCG AGA ACG CGA GCG ATT 3’ 
R – 5’ GAC CAA TCC AAC CGA AAC 3’ 
Probe 
5’ HEX – CTT ACA AAA AAC CTT CCG AAT ACG TTC CGA 
– Iowa Black RQ-Sp 3’ 
RASSF1A 
Primers 
F – 5’ AGC GAA GTA CGG GTT TAA TC 3’ 
R – 5’ ACA CGC TCC AACC GA ATA 3’ 
Probe 5’ NED – CGG GAG TTG GTA TTC GTT GGG CG – QSY 3’ 
SCGB3A1 
Primers 
F – 5’ GTA CGG TCG TGA GCG GAG C 3’ 
R – 5’ GAA ACT TCT TAT ACC CGA TCC TC 3’ 
Probe 
5’ FAM – GCC GAC CTC GCC CGC GCT CCT AAA – Iowa 
Black RQ-Sp 3’ 
SEPT9 
Primers 
F – 5’ TTA GTT AGC GCG TAG GGT TC 3’ 
R – 5’ ACC TTC GAA ATC CGA AAT AA 3’ 
Probe 
5’ NED – GCG TTA ACC GCG AAA TCC GAC ATA ATA 
ACT – QSY 3’ 
SHOX2 
Primers 
     F – 5’ ATT CGT ATT TGG TCG CGT AC 3’ 
   R – 5’ CTA CTA CGA CCG CCA CTA CC 3’ 
Probe 5’ FAM – CAA CGT AAC GAA CG – MGB 3’ 
SOX17 
Primers 
F – 5’ GAT CGG TTC GTT TTC GTC G 3’ 
R – 5’ GCC CGT ATT CTA ACC TAT CG 3’ 
Probe 
5’ Cy5 – ACC GAC CTA ATA ACA CTA CGA ACG C – Iowa 
Black RQ-Sp 3’ 
 
 The multiplex qMSP assays were carried out in 96-well plates (GRiSP, Portugal) 
using a 7500 Sequence Detector (Applied Biosystems, Perkin Elmer, CA, USA). The 
multiplex gene combinations used are displayed in Table 9.  
 
 
 
 
 
 
 
 
 
Table 9. Gene combinations for multiplex qMSP. 
Combination 1 Combination 2 Combination 3 
β-Actin MGMT RARβ2 
APC SEPT9 SCGB3A1 
FOXA1 SHOX2 SOX17 
RASSF1A –– –– 
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 For gene combinations 1 and 2, per well: 10 µL Xpert Fast Probe (GRiSP, Portugal), 
0.8 µL of a mix with forward and reverse primers (10 µM) (Sigma-Aldrich, Germany), 0.1 µL 
of TaqMan probe (10 µM) (Applied Biosystems), 6 µL of amplified DNA and sterile distilled 
water (B.Braun, Melsungen, Germany) were added, totaling 20 µL of reaction volume. For 
combination 3, per well: 10 µL Xpert Fast Probe, 0.3 µL of each Primer PCR Custom Assay 
(BioRad, United States), 6 µL of amplified DNA and sterile distilled water were added, in a 
final volume of 20 µL.  
 
 The PCR program used was the following: 1 cycle at 95ºC for 3 min.; 50 cycles at 
95ºC for 5 seconds and 60ºC for 30 seconds. All samples were run in triplicate and three 
negative template controls (WGA-amplified water) were included in each plate. In addition, 
CpGenome™ Universal Methylated DNA (Merck Millipore, Germany) underwent WGA and 
was used as a template to six serial dilutions (5x factor dilution), which were included in 
each plate. These serial dilutions were used to generate a standard curve, which allowed 
the relative quantification and PCR efficiency evaluation. All plates presented efficiency 
values above 90%.  
 
 The relative DNA methylation levels for each gene in each sample was calculated 
using the following formula: 
𝑀𝑒𝑡ℎ𝑦𝑙𝑎𝑡𝑖𝑜𝑛 𝑙𝑒𝑣𝑒𝑙 =
𝑇𝑎𝑟𝑔𝑒𝑡 𝑔𝑒𝑛𝑒
𝛽 − 𝐴𝑐𝑡𝑖𝑛
× 1000 
STATISTICAL ANALYSIS  
 Non-parametric tests were used to compare methylation levels of each gene 
promoter between cases and respective controls and to evaluate associations with 
clinicopathological features. Mann-Whitney U test was used for comparisons between two 
groups and Kruskall-Wallis test for three or more groups, followed by Mann-Whitney U test 
with Bonferroni’s correction for pairwise comparisons. Correlations between methylation 
levels and age were assessed by Spearman nonparametric correlation test. A p value <0.05 
was considered statistically significant. 
 For each gene, samples were categorized as methylated or unmethylated based on 
cut-off value determined using Youden’s J index (value combining highest sensitivity and 
specificity), through ROC curve analysis (175). Validity estimates [sensitivity, specificity, 
positive predictive value (PPV), negative predictive value (NPV) and accuracy] were 
calculated to assess biomarker performance (Table 10). A positive result was considered 
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when a sample was classified as methylated and negative when unmethylated. Gene 
panels were constructed to maximize detection performance, considering a positive result 
whenever at least one gene promoter was methylated. The validity estimates for 
“PanCancer” panel were determined by assembling BrC + CRC + LC samples (n=253) vs. 
AC samples (n=103). For “CancerType” panel, the cut-offs were determined based on the 
following combinations: (i) for SCGB3A1, BrC samples (n=108) vs. CRC + LC samples 
(n=145); (ii) SEPT9, CRC samples (n=72) vs. BrC + LC samples (n=181); (iii) SOX17, LC 
samples (n=73) vs. BrC + CRC samples (n=180).  A multiple ROC curves via resampling 
analysis was performed in order to calculate the validity estimates for “PanCancer” and 
“CancerType” panels. Briefly, the samples were randomly divided in a training (70%) and 
validation (30%) sets. The cut-off value comprising the highest sensitivity and specificity 
was estimated in the training set and the validity estimates were calculated in the validation 
set using that cut-off. This procedure was repeated 1,000 times, and the mean of the 
sensitivities and specificities was calculated. These calculations were performed using R 
v3.4.4. Two-tailed p-values calculation and other ROC curve analyses were performed 
using a computer assisted program (SPSS Version 24.0, Chicago, IL, USA). Graphics were 
assembled with GraphPad 6 Prism (GraphPad Software, La Jolla, CA, USA). 
 
Table 10. Formulas for biomarkers performance calculations. 
Tumor vs. Control  Sensitivity (%) (C/E) ×100 
 Tumor Control  Specificity (%) (B/F)×100 
< cut-off A B  PPV (%) (C/(C+D))×100 
> cut-off C D  NPV (%) (B/(A+B))×100 
Total E F  Accuracy (%) [(C+B)/(E+F)] 
Abbreviations: PPV – Positive Predictive Value; NPV – Negative Predictive Value. 
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CLINICAL AND PATHOLOGICAL DATA 
 This study included 253 female patients with BrC (n=108), CRC (n=72) or LC (n=73) 
and 103 female healthy donors (AC), which served as controls. Detailed clinical and 
pathological characterization is provided in Table 11. Globally, the median age of cancer 
patients significantly differed from that of controls (p<0.0001), and, thus, correlations 
between age and gene promoter methylation levels were assessed stratifying for ACs and 
cancer patients. Although SOX17 promoter’s methylation levels correlated with controls’ 
age (R=0.225, p=0.009), this was not observed in cancer patients and no other correlations 
were disclosed. 
 
Table 11. Clinical and pathological features of BrC, CRC and LC patients and ACs enrolled in this study. 
Clinicopathological features AC Cancer Patients 
Number 103 253 
Age median (range) 52 (45-65) 63 (29-93) 
  Breast cancer 
Histological Type 
n.a. 
 
Invasive Carcinoma, no special type (NST) 80 
Invasive lobular carcinoma 12 
Ductal carcinoma in situ 7 
Other invasive carcinoma subtypesa 9 
Estrogen Receptor Statusb   
Positive n.a. 91 
Negative  15 
Progesterone Receptor Statusc   
Positive  n.a. 81 
Negative  24 
Molecular Subtyped 
n.a. 
 
Luminal 90 
ERBB2 overexpression  4 
TNBC 10 
Primary Tumor (T)  
n.a. 
 
Tis 7 
T1 / T2 95 
T3 / T4 6 
Regional lymph node (N) 
n.a. 
 
N0 65 
N+ 43 
Distant metastasis (M) 
n.a. 
 
M0 103 
M1 3 
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Clinical Stage 
n.a. 
 
0 7 
I / II 88 
III / IV 13 
  Colorectal cancer 
Histological Type 
n.a.  
 
Premalignant Lesionse 3 
Adenocarcinoma (all subtypes) 68 
Neuroendocrine carcinoma 1 
Tumor location    
Proximal colon 
n.a. 
23 
Distal colon 30 
Rectum 19 
Primary tumor (T)b 
n.a. 
 
Tis 3 
T1 / T2 18 
T3 / T4 49 
Regional lymph node (N)b 
n.a. 
 
N0 37 
N+ 33 
Distant metastasis (M) 
n.a. 
 
M0 66 
M1 6 
Clinical Stage 
n.a. 
 
0 3 
I / II 34 
III / IV 35 
  Lung cancer 
Histological Type 
n.a. 
 
Non-small cell lung carcinoma (NSCLC)  
Adenocarcinoma 56 
Other NSCLC subtypesf 8 
Small-cell lung carcinoma (SCLC)  8 
Carcinoid tumor 1 
Primary Tumor (T)d 
n.a.  
 
T1 18 
T2 / T3 / T4 51 
Regional lymph node (N)g   
N0 n.a. 27 
N+  45 
Distant metastasis (M) 
n.a. 
 
M0 36 
M1 37 
 
 
 
 
 
 
 
 
RESULTS | 41 
 
Clinical Stage 
I / II 
 
n.a. 
 
21 
III / IV 52 
aIncludes medullary, mucinous and mixed type carcinoma (invasive carcinoma, NST and micropapillary 
carcinoma); bNot determined in 2 cases; cNo information available in 3 cases; dNo information available in 4 
cases; eIncludes tubulovillous adenoma with high-grade dysplasia and intramucosal adenocarcinoma; fIncludes 
squamous cell carcinoma and large-cell neuroendocrine carcinoma; gNot possible to determine in 1 case; AC, 
Asymptomatic Control; n.a. – not applicable 
 
GENE PROMOTER METHYLATION LEVELS IN ccfDNA 
 The gene promoter methylation levels of APC, FOXA1, MGMT, RARβ2, RASSF1A, 
SCGB3A1, SEPT9, SHOX2 and SOX17 were evaluated in ccfDNA extracted from cancer 
patients and ACs plasma samples. APC, FOXA1, RASSF1A and SCGB3A1 promoters 
depicted significantly higher methylation levels in BrC patients than in controls (p<0.0001, 
p=0.0063, p=0.0003 and p=0.0245, respectively) (Figure 9). Nonetheless, no significant 
differences were found for MGMT, RARβ2, SHOX2, SEPT9 and SOX17 (p=0.984, p=0.611, 
p=0.090, p=0.168 and p=0.815, respectively) (Figure 9).  
 
Figure 9. Scatter plot of the distribution of (A) APC, (B) FOXA1, (C) MGMT, (D) RARβ2, (E) RASSF1A, (F) 
SCGB3A1, (G) SEPT9, (H) SHOX2 and (I) SOX17 promoters’ methylation levels in BrC patients (n=108) and 
ACs (n=103). Mann Whitney Test, n.s. p>0.05, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
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 In CRC patients, APC, FOXA1, RARβ2, RASSF1A, SCGB3A1, SEPT9 and SOX17 
methylation levels were significantly higher than in controls (p=0.005, p<0.0001, p=0.009, 
p=0.012, p=0.003, p=0.001 and p=0.007, respectively) (Figure 10), although no differences 
were apparent for MGMT and SHOX2 methylation levels (p=0.074 and p=0.077, 
respectively) (Figure 10). 
 
Figure 10. Scatter plot of the distribution of (A) APC, (B) FOXA1, (C) MGMT, (D) RARβ2, (E) RASSF1A, (F) 
SCGB3A1, (G) SEPT9, (H) SHOX2 and (I) SOX17 promoters’ methylation levels between CRC patients (n=72) 
and ACs (n=103). Mann Whitney Test, n.s. p>0.05, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. Black 
horizontal line represents the methylation levels’ median. 
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 Concerning LC, significantly higher methylation levels compared to controls were 
disclosed for APC, FOXA1, RARβ2, RASSF1A and SOX17 (p<0.0001 for all genes), 
whereas MGMT, SCGB3A1 and SHOX2 did not display differences between LC patients 
and ACs (p=0.400, p=0.084 and p=0.214, respectively) (Figure 11). 
 
Figure 11. Scatter plot of the distribution of (A) APC, (B) FOXA1, (C) MGMT, (D) RARβ2, (E) RASSF1A, (F) 
SCGB3A1, (G) SHOX2 and (H) SOX17 promoters’ methylation levels between LC patients (n=73) and ACs 
(n=103). SEPT9 only presented zero values for AC and LC patients. Mann Whitney Test, n.s. p>0.05, *p<0.05, 
**p<0.01, ***p<0.001, ****p<0.0001. Black horizontal line represents the methylation levels’ median. 
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ASSOCIATION BETWEEN PROMOTERS’ METHYLATION LEVELS AND 
CLINICOPATHOLOGICAL FEATURES 
 Methylation levels of tested gene promoters were associated with several 
clinicopathological features. Specifically, in BrC patients, RASSF1A methylation levels 
significantly differed between PR+ and PR- tumors (p=0.031) (Figure 12A), whereas RARβ2 
promoter methylation levels were higher in node-positive than in node-negative BrC patients 
(p=0.008) (Figure 12B). 
 
Figure 12. Scatter plot of (A) RASSF1A promoter’s methylation levels between positive and negative 
Progesterone Receptor (Negative n=24, Positive n=94) and (B) RARβ2 promoter’s methylation levels between 
node-negative and node-positive BrC patients (Negative n=65, Positive n=43). Mann Whitney Test, *p<0.05, 
**p<0.01. 
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 Moreover, in CRC patients, SEPT9 promoter methylation levels were significantly 
higher in patients with stage IV or distant metastatic disease (M1) (p<0.0001, in all 
comparisons) (Figure 13B). Similar results were depicted for APC, SHOX2 and SOX17 
promoter methylation in metastatic vs. non-metastatic CRC patients (p=0.0276, p=0.0107 
and p=0.0242, respectively), although no differences were found for stage (Figure 13).  
 
Figure 13. Scatter plot of (A) APC, (B) SEPT9, (C) SHOX2 and (D) SOX17 promoter’s methylation levels 
between metastatic CRC patients (M1) and non-metastatic CRC patients (M0) (M0 n=66, M1 n=6). Mann 
Whitney Test, *p<0.05, ****p<0.0001. 
 
 Concerning LC, significantly higher APC and RARβ2 promoter methylation levels 
were apparent in SCLC patients than those with adenocarcinoma (p=0.005 and p=0.035, 
respectively) (Figure 14A, Figure 14B). Moreover, node-positive LC patients displayed 
higher RASSF1A methylation levels than node-negative LC patients (p=0.018, Figure 14C), 
whereas higher SOX17 promoter methylation was observed in patients with systemic 
metastization (p=0.029) (Figure 14D).  
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Figure 14. Scatter plot of (A) APC and (B) RARβ2 promoters’ methylation levels for Histological Subtype 
(Adenocarcinoma n=55, SCLC n=8), (C) RASSF1A promoter’s methylation levels for Regional Node (N) status 
(Negative=27, Positive=45) and (D) SOX17 promoter’s methylation levels between metastatic LC patients (M1) 
and non-metastatic LC patients (M0) (M0 n=36, M1 n=37). Mann Whitney Test, *p<0.05, **p<0.01. Black 
horizontal line represents the methylation levels’ median.  
 
BIOMARKER PERFORMANCE OF ccfDNA 
 Gene promoters disclosing significantly higher methylation levels in cancer patients 
vs. controls were selected for assessment of BrC, CRC or LC detection performance in 
ccfDNA. APC, FOXA1 and RASSF1A individually depicted sensitivity over 20% and 
specificity greater than 70%, for all cancers. FOXA1 displayed the highest sensitivity (39% 
for BrC, 50% for CRC and 73% for LC) (Table 12). Overall RASSF1A disclosed the highest 
specificity (over 98%) for all three cancer types and SEPT9 displayed 100% specificity for 
CRC detection (Table 12). SCGB3A1 detected BrC and CRC with over 20% sensitivity 
(Table 12), whereas RARβ2 and SOX17 displayed specificity higher than 90% for CRC and 
LC detection (Table 12).  
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Table 12. Biomarker performance of each promoter’s gene methylation for BrC, CRC and LC detection in 
ccfDNA. 
Abbreviations: PPV - Positive Predictive Value; NPV - Negative Predictive Value; n.a. - not applicable 
 
 Since APC, FOXA1 and RASSF1A were biomarkers common to BrC, CRC and LC, 
they were further tested as gene panel for cancer detection (designated “PanCancer”), 
whereas RARβ2, SCGB3A1, SEPT9 and SOX17 were considered a gene panel for 
discrimination of primary cancer localization (“CancerType” panel). In ccfDNA, the 
“PanCancer” panel correctly detected 183 out of 253 cancer cases, corresponding to 72.4% 
sensitivity, 73.5% specificity and 72.8% accuracy (Table 13, Figure 15). Furthermore, 
“PanCancer” panel detected CRC stages 0, I and II with 78.38% sensitivity, 69.90% 
specificity, 48.33% PPV, 90.00% NPV and 72.14% accuracy, and early LC with 85.71% 
sensitivity, 75.73% specificity, 41.86 % PPV and 96.30% NPV. 
Genes 
Cut-off 
value 
Sensitivity 
% 
Specificity 
% 
PPV  
% 
NPV 
 % 
Accuracy 
% 
Breast Cancer 
APC 6.710 32.41 94.17 85.37 57.06 62.56 
FOXA1 68.01 38.89 79.61 66.67 55.41 58.77 
RASSF1A 24.88 19.44 100.0 100.0 54.21 58.77 
SCGB3A1 4.130×10-3 21.30 92.23 74.19 52.78 55.92 
Colorectal Cancer 
APC 4.711 20.83 94.17 71.43 62.99 64.00 
FOXA1 142.4 50.00 88.35 75.00 71.65 72.57 
RARβ2 3.949 16.67 95.15 70.59 62.03 62.86 
RASSF1A 39.47 13.89 99.03 90.91 62.20 64.00 
SCGB3A1 6.291×10-5 26.39 90.29 65.52 63.70 64.00 
SEPT9 8.973 11.11 100.0 100.0 61.68 63.43 
SOX17 0.6633 23.61 90.29 62.96 62.84 62.86 
Lung Cancer 
APC 4.115 35.62 94.17 81.25 67.36 69.89 
FOXA1 30.12 72.60 73.79 66.25 79.17 73.30 
RARβ2 3.056 24.66 95.15 78.26 64.05 65.91 
RASSF1A 26.57 21.92 98.06 88.89 63.92 66.48 
SOX17 28.16 38.36 95.15 84.85 68.53 71.59 
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Table 13. Biomarker performance detection of “PanCancer” panel (APC, FOXA1 and RASSF1A) in ccfDNA. 
 
 
 
 
 
 
 
Figure 15. Percentage of cases identified by “PanCancer” panel in cancer samples (Positive 72%, Negative 
28%) and ACs (Positive 26%, Negative 74%). 
 
 Using the “CancerType” panel, three methylated genes might be used to indicate 
the most likely primary location of the tumor detected by the “PanCancer” panel (Table 14, 
Table 15). SCGB3A1 detected BrC with 80.69% specificity, whereas SEPT9 methylation 
detected CRC with 98.90% specificity and SOX17 detected LC with 85.56% specificity 
(Table 15). RARβ2 was not further included in “CancerType” since it was not useful for 
discrimination between CRC and LC (data not shown). The results of the “CancerType” 
panel could, then, be used to select the best strategy for identification of primary localization 
(mammography, colonoscopy or LDCT). 
 
 
 
 
 PanCancer 
Sensitivity % 72.4 
Specificity % 73.5 
Positive Predictive Value % 87.1 
Negative Predictive Value % 52.1 
Accuracy % 72.8 
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“+” indicates a higher probability to find that cancer; “‒” denotes that there is a low probability for that cancer 
type be present. Abbreviations: BrC – Breast Cancer; CRC – Colorectal Cancer; LC – Lung Cancer 
 
Table 15. Performance of gene promoter combinations for discrimination among BrC, CRC and LC 
(“CancerType” panel).  
  SCGB3A1 SEPT9 SOX17 
Breast 
cancer 
Sensitivity % 16.8 - - 
Specificity % 80.0 - - 
Accuracy % 53.0 - - 
Colorectal 
cancer 
Sensitivity % - 11.1 - 
Specificity % - 98.9 - 
Accuracy % - 73.9 - 
Lung 
cancer 
Sensitivity % - - 39.4 
Specificity % - - 85.1 
Accuracy % - - 71.9 
 
 
 
 
 
 
 
 
 
 
 
 
Table 14. Methylated gene promoter combinations for BrC, CRC and LC discrimination using the “CancerType” 
panel. 
Gene BrC CRC LC 
SCGB3A1 + ‒ ‒ 
SEPT9 ‒ + ‒ 
SOX17 ‒ ‒ + 
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 BrC, CRC and LC are the most incident and lethal neoplasms among women in 
developed regions of the globe (1) and screening programs may decrease mortality through 
increased detection of early stage disease (17, 50, 176). Mammography and colonoscopy 
are gold-standard for BrC and CRC screening, whereas LDCT is recommended for high-
risk smokers’ screening (17, 52, 62). Notwithstanding, these screening tools have significant 
limitations, comprising risk of overdiagnosis/overtreatment, invasiveness and high cost, 
entailing low compliance, and suboptimal specificity, requiring further testing and increasing 
suspects’ anxiety (19, 50). Hence, low-invasive screening strategies, capable of better 
triaging cancer suspects for testing with highly specific methods is an important clinical 
challenge. Owing to the ubiquity and cancer-specificity of selected aberrant gene promoter 
methylation, enabling successful cancer detection in liquid biopsies (95), we assessed the 
feasibility of ccfDNA analysis using multiplex qMSP for simultaneous BrC, CRC and LC 
detection in women. 
 Gene methylation levels were assessed in ccfDNA extracted from plasma of BrC, 
CRC and LC patients and ACs. The amount and quality of plasma ccfDNA is low, and the 
sodium-bisulfite modification leads to further DNA degradation, which hinders ccfDNA 
methylation analysis (171). In this study, due to sample collection limitations, ccfDNA was 
extracted from 3 mL of plasma, a reduced amount comparing with other studies (111, 177). 
Nonetheless, WGA of bisulfite-converted ccfDNA allowed to increase DNA quantity and, 
thus, multiplex qMSP sensitivity. Several reports showed that WGA produce unbiased 
amplified products that can be used in methylation analysis when the DNA quantity is limited 
(172, 178). 
 MethyLight qMSP is one of the most commonly used method for assessing genes’ 
methylation status (112, 135). It requires primers and probes designed specifically for the 
bisulfite-converted DNA sequence. Although MethyLight is useful in methylation studies, it 
allows for single gene analysis, which can be limiting for samples with low DNA quantity. A 
multiplex qMSP reaction allows for the analysis of several targets in a single PCR reaction 
(179), hence it displays several advantages: (i) requires low amounts of DNA; (ii) is a faster 
and more efficient method than singleplex qMSP and (iii) less amounts of reagents are 
necessary (180), which is suitable to study DNA methylation in ccfDNA extracted from 
plasma/serum (155). Indeed, its usefulness in ccfDNA liquid biopsies was previously 
demonstrated (109, 113, 155). In this study we assessed the promoters’ methylation levels 
of 9 genes plus β-Actin as a reference gene using a four-color multiplex assay. 
Nevertheless, primers and probes design might be one of the limitations associated with 
multiplex qMSP, since it is important to avoid non-specific links between primers and 
probes, and to assure target gene specificity. Furthermore, the ABI 7500 Real-Time PCR 
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system used in this study only allows five different fluorescent dyes (passive dye ROX plus 
four fluorescent dyes). Still, this limitation might be overcome by using platforms with more 
fluorescent channels (179). Importantly, herein, we demonstrate that multiplex qMSP is 
useful for analyzing in samples with minutes amounts of DNA, such as ccfDNA extracted 
from plasma/serum.  
 Candidate genes were selected based on an extensive and critical literature review, 
including our previously published results (166-168), and, globally, our findings are mostly 
in line with previous publications. For BrC, we confirmed APC, FOXA1, RASSF1A and 
SCGB3A1 hypermethylation in ccfDNA, in accordance with published studies (111, 112, 
130, 135), whereas RARβ2 methylation findings paralleled some previous studies (111, 
132, 181), but not others, either in tissue (180), fine-needle washings (167) or serum (127, 
135, 182). Differences in methodology (127), population (135) and/or biological sample type 
(167, 180) likely explain these dissimilarities. Furthermore, SOX17 promoter has been 
reported as aberrantly methylated in ccfDNA and CTCs from BrC patients’ (124, 183), albeit 
its BrC biomarker potential requires further investigation. As for CRC, the significantly higher 
APC, FOXA1, RARβ2, RASSF1A, SCGB3A1, SEPT9 and SOX17 methylation levels in 
cancer patients are in line with previous publications (168, 184-189), although divergent 
results have been reported for MGMT (115, 168, 190). Concerning LC, and except for 
SHOX2, our results are in accordance with previous studies (114, 123, 126, 163, 191-193). 
To the best of our knowledge, this is the first study disclosing FOXA1 methylation in CRC 
and LC patients’ ccfDNA. 
 Some interesting clinicopathological correlates with gene promoter methylation 
status were disclosed. The association of RASSF1A promoter methylation with PR status 
parallels previous reports (194-196) and higher RARβ2 methylation in node-positive BrC is 
in line with previous findings in sentinel lymph node metastasis (197, 198). Furthermore, 
some of the tested candidate genes might also convey relevant prognostic information, as 
APC, SEPT9, SHOX2 and SOX17 methylation levels were increased in CRC patients with 
distant metastasis. Interestingly, a recent study disclosed higher SEPT9 and SHOX2 
methylation levels in ccfDNA of CRC patients with distant metastasis and advanced stages 
(199). Moreover, a correlation between APC methylation and more advanced CRC stage 
was previously established in CRC tissue analysis (200) and APC methylation was also 
found in CRC hepatic metastasis (201). Another interesting finding was the higher APC and 
RARβ2 methylation levels in patients with SCLC vs. lung adenocarcinoma. Recently, a 
microRNA-based test (miRview®) test was approved for discrimination among LC subtypes 
(202), based on analysis of pre-operative biopsies, which might be difficult to obtain. Thus, 
gene promoter methylation assessment in ccfDNA might prove advantageous in lung 
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tumors with difficult access, since SCLC requires a specific treatment regimen and is 
associated with worse prognosis (203). Furthermore, an association between RASSF1A 
methylation and node-positive LC patients was found, which is in accordance with previous 
publications demonstrating higher RASSF1A methylation levels in more advanced tumor 
stage, associating with local recurrence and worse prognosis in LC patients (204, 205). 
Finally, SOX17 promoter methylation levels associated with distant metastasis, in 
agreement with previous studies using plasma samples from LC patients (123). 
 Although several gene methylation panels have been proposed for specific cancer 
detection using ccfDNA (111-114), our main goal was to devise a gene panel enabling the 
simultaneous detection of the three most common cancers among women, thus potentially 
increasing the cost-effectiveness of a methylation-based screening test. Remarkably, 
similar sensitivity and specificity was disclosed by the “PanCancer” panel (APC, FOXA1 
and RASSF1A) compared to other gene methylation panels proposed for individual BrC, 
CRC and LC detection (111-114). Compared to mammography, “PanCancer” discloses 
lower sensitivity and specificity (14), but it may result advantageous for triaging women for 
mammographic screening, eventually decreasing cumulative radiation exposure and costs, 
while increasing women’s compliance. It would be interesting to ascertain whether the 
molecular test might provide more accurate screening results than mammography in 
women with high breast density, for which mammography is mostly ineffective. Optimally 
performed colonoscopy detects CRC with 58-75% sensitivity, depending on the localization 
of the tumor (206), and allows for confirmatory tumor biopsy and polyp removal (52). 
Nevertheless, it is a costly, invasive approach that requires prior preparation and sedation 
(52), whereas FOBT tests are non-invasive but have limited sensitivity and specificity (52). 
The “PanCancer” panel disclosed similar detection performance to colonoscopy and 
superior to fecal occult blood tests, constituting a minimally-invasive test, amenable for 
screening. Finally, “PanCancer” panel clearly outperformed LDCT for LC detection and 
might be favorably used in a pre-screening context, to better identify high-risk suspects of 
harboring LC (Figure 16). Interestingly, the “PanCancer” panel detected stage I and II LC 
with a high sensitivity and specificity, and may, thus, constitute a novel option for LC early 
detection. Furthermore, it is likely that lesions difficult to diagnose by imaging techniques 
might be detectable using the “PanCancer” panel as Shan et al. have previously 
demonstrated that a methylation-based panel detected small breast tumors (< 1 cm) with 
higher sensitivity than mammography (112). 
 Identifying the putative cancer primary localization following a positive “PanCancer” 
panel result constitutes the next challenge. Based on the individual performance of the 
remainder gene promoters tested, we proposed another panel (“CancerType”) which 
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attempts to indicate the most likely topography of the primary tumor. To increase cost-
effectiveness, this panel would only be performed in “PanCancer” positive cases, allowing 
cancer suspects to be directed for mammography, colonoscopy or LDCT (Figure 16). 
Although “CancerType” genes individually display low sensitivity, the main goal of this panel 
is to discriminate among the three cancer types, requiring high specificity. Risk factors 
should be also considered (e.g., familial history of BrC or CRC, tobacco exposure) to 
improve the detection strategy. In cases in which no tumor is found, looking for the 
remainder possible localizations should be guided according to clinical evaluation. Repeat 
testing after a defined time could also be considered. It is difficult, however, to estimate how 
results of the “CancerType” panel would perform in a real setting as it assessment implies 
a carefully designed study with relatively long follow-up period. 
 The main limitations of this study are the limited number of samples tested and the 
lack of long term follow-up, which would be required to determine whether asymptomatic 
controls testing positive would subsequently develop BrC, CRC or LC. These limitations 
also preclude an accurate estimate of the use of the two gene panels in a “real world” 
scenario. Nevertheless, it should be emphasized that our proposal is innovative and might 
foster the development of more accurate and cost-effective tools for BrC, CRC and LC 
screening. 
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Figure 16. Schematic representation of a proposed algorithm for screening and management of breast, 
colorectal and lung cancers using the methylation panels. If “PanCancer” panel positive, “CancerType” panel 
would be performed in order to determine the cancer type present. After “CancerType”, exams such as 
mammography, colonoscopy or low-dose computed tomography (LDCT) would be executed to confirm the 
diagnosis. If “PanCancer” panel negative, a re-screening would be proposed, whereas if “CancerType” panel 
negative, a clinical evaluation or a re-screening would be options. Nunes SP unpublished  
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 A selected gene promoter methylation assessment in ccfDNA is promising for 
simultaneous screening of BrC, CRC and LC, the major causes of cancer-related morbidity 
and mortality in women. The panels might complement current screening modalities, 
perfecting the triage of cancer suspects, increasing compliance and cost-effectiveness. 
Large-scale studies are now required to validate these findings and define the best 
algorithm for clinical application of these minimally-invasive methylation-based tests.   
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APPENDIX I 
Breast Cancer TNM Staging 
 
Table 1. TNM classification of BrC according to AJCC/UICC guidelines (Adapted from (27)). 
T – Primary Tumor (Clinical and Pathological) 
Tx Primary tumor cannot be assessed 
T0 No evidence of primary tumor 
Tis (DCIS) Ductal carcinoma in situ 
T1 Tumor ≤ 20 mm in greatest dimension 
T2 Tumor >20 and ≤ 50 mm in greatest dimension 
T3 Tumor > 50 in greatest dimension 
T4 
Tumor of any size with direct extension to the chest wall and/or to the skin; 
Inflammatory carcinoma 
N – Regional Lymph Nodes (Clinical and Pathological) 
Nx Regional lymph nodes cannot be assessed 
N0 No regional node metastases 
N1 
cN1* Metastasis to movable ipsilateral Level I, II axillary lymph node(s) 
pN1** Micrometastasis or macrometastasis in 1-3 axillary lymph nodes 
N2 
cN2 Metastasis in ipsilateral level I, II axillary lymph nodes that are clinically fixed 
or matted or ipsilateral internal mammary nodes in the absence of axillary lymph 
node metastasis 
pN2 Metastasis in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary 
lymph nodes by imaging in the absence of axillary node metastasis 
N3 
cN3 Metastasis in ipsilateral infraclavicular lymph node(s), ipsilateral internal 
mammary lymph node metastasis or metastasis in ipsilateral supraclavicular lymph 
node(s) 
pN3 Metastasis in 10 or more axillary lymph nodes or in infraclavicular lymph nodes, 
positive ipsilateral internal mammary lymph nodes by imaging in the presence of 
one or more positive Level I, II  axillary nodes, more than 3 axillary lymph node 
metastasis by sentinel lymph node biopsy in clinically negative ipsilateral internal 
mammary lymph nodes or in ipsilateral supraclavicular lymph nodes 
M – Distant Metastasis (Clinical and Pathological) 
M0 No clinical or radiographic evidence of distant metastasis 
M1 
Distant metastasis detected by clinical and radiographic means and/or histologically 
proven metastasis larger than 0.2mm 
* Clinical stage; ** Pathological stage; DCIS – Ductal carcinoma in situ  
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Table 2. BrC staging with the correspondent TNM classification. Adapted from (27). 
Primary  
Tumor (T)  
Regional Lymph 
Node (N) 
Distant Metastasis 
(M) 
Stage 
Tis N0 M0 0 
T1 N0 M0 IA 
T0 N1mi M0 IB 
T1 N1mi M0 IB 
T0 N1 M0 IIA 
T1 N1 M0 IIA 
T2 N0 M0 IIA 
T2 N1 M0 IIB 
T3 N0 M0 IIB 
T0 N2 M0 IIIA 
T1 N2 M0 IIIA 
T2 N2 M0 IIIA 
T3 N1 M0 IIIA 
T3 N2 M0 IIIA 
T4 N0 M0 IIIB 
T4 N1 M0 IIIB 
T4 N2 M0 IIIB 
Any T N3 M0 IIIC 
Any T Any N M1 IV 
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APPENDIX II 
Colorectal Cancer TNM Staging 
 
Table 3. TNM classification of CRC according to AJCC/UICC guidelines (Adapted from (27)). 
T – Primary Tumor 
Tx Primary tumor cannot be assessed 
T0 No evidence of primary tumor 
Tis Carcinoma in situ, intramucosal carcinoma  
T1 
Tumor invades the submucosa (through the muscularis mucosa but not into 
muscularis propria) 
T2 Tumor invades the muscularis propria 
T3 Tumor invades through the muscularis propria into pericolorectal tissues 
T4 
Tumor invades the visceral peritoneum or invades or adheres to adjacent organ or 
structure 
T4a Tumor invades through the visceral peritoneum  
T4b Tumor directly invades or adheres to adjacent organs or structures  
N – Regional Lymph Nodes  
Nx Regional lymph nodes cannot be assessed 
N0 No regional node metastases 
N1 
One or three regional lymph nodes are positive, or any number of tumor deposits 
are present and all identifiable lymph nodes are negative 
N1a One regional lymph node is positive 
N1b Two or three regional nodes are positive 
N1c No regional nodes are positive, but there are tumor deposits in the subserosa, 
mesentery or nonperitonealized pericolic, or perirectal/mesorectal tissues 
N2 
Four or more regional nodes are positive 
N2a Four to six regional lymph nodes are positive 
N2b Seven or more regional lymph nodes are positive  
M – Distant Metastasis  
M0 No distant metastasis by imaging  
M1 
Metastasis to one or more distant sides or organs or peritoneal metastasis is 
identified 
M1a Metastasis to one site or organ is identified without peritoneal metastasis 
M1b Metastasis to two or more sites or organs is identified without peritoneal 
metastasis 
M1c Metastasis to the peritoneal surface is identified alone or with other site or 
organ metastasis  
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Table 4. CRC staging with the correspondent TNM classification. Adapted from (27). 
Primary  
Tumor (T)  
Regional Lymph 
Node (N) 
Distant Metastasis 
(M) 
Stage 
Tis N0 M0 0 
T1, T2 N0 M0 I 
T3 N0 M0 IIA 
T4a N0 M0 IIB 
T4b N0 M0 IIC 
T1, T2 N1/N1c M0 IIIA 
T1 N2a M0 IIIA 
T3-T4a N1/N1c M0 IIIB 
T2-T3 N2a M0 IIIB 
T1-T2 N2b M0 IIIB 
T4a N2a M0 IIIC 
T3-T4a N2b M0 IIIC 
T4b N1-N2 M0 IIIC 
Any T Any N M1a IVA 
Any T Any N M1b IVB 
Any T Any N M1c IVC 
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APPENDIX III 
Lung Cancer TNM Staging 
  
Table 5. TNM classification of LC according to AJCC/UICC guidelines (Adapted from [25]). 
T – Primary Tumor  
Tx 
Primary tumor cannot be assessed, or tumor proven by the presence of malignant 
cells in sputum or bronchial washing but not visualized by imaging or bronchoscopy 
T0 No evidence of primary tumor 
Tis 
Carcinoma in situ 
Squamous cell carcinoma in situ (SCIS)  
Adenocarcinoma in situ (AIS): adenocarcinoma with pure lepidic pattern. ≤3 cm in 
greatest dimension 
T1 
Tumor ≤3 in greatest dimension, surrounded by lung or visceral pleura without 
bronchoscopic evidence of invasion more proximal than lobar bronchus  
T1mi Minimally invasive adenocarcinoma: adenocarcinoma (≤3 cm in greatest 
dimension) with a predominantly lepidic pattern and ≤5 mm invasion in greatest 
dimension 
T1a Tumor ≤1 cm in greatest dimension. A superficial, spreading tumor of any size 
whose invasive component is limited to the bronchial wall and may extend proximal 
to the main bronchus also is classified as T1a, but these tumors are uncommon 
T1b Tumor >1cm but ≤2 cm in greatest dimension 
T1c Tumor >2 cm but ≤3 cm in greatest dimension  
T2 
Tumor >3 cm but ≤5 cm or having any of the following features: 
 Involves the main bronchus regardless of distance to the carina, but without 
involvement of the carina; 
 Invades visceral plaura; 
 Associated with atelectasis or obstructive pneumonitis that extends to the 
hiliar region, involving part or all of the lung. 
T2a Tumor >3 cm but ≤4 cm in greatest dimension 
T2b Tumor >4 cm but ≤5 cm in greatest dimension  
T3 
Tumor >5 cm but ≤7 cm in greatest dimension or directly invading any of the 
following: parietal pleura, chest wall, pherenic nerve, parietal pericardium; or 
separate tumor nodule(s) in the same lobe as the primary 
T4 
Tumor >7 cm or tumor of any size invading one or more of the following: diaphragm, 
mediastinum, heart, esophagus, vertebral body, or carina; separate tumor nodule(s) 
in an ipsilateral lobe different from that of the primary  
N – Regional Lymph Nodes  
Nx Regional lymph nodes cannot be assessed 
N0 No regional node metastases 
N1 
Metastasis in ipsilateral peribronchial and/or ipsilateral hiliar lymph nodes and 
intrapulmonary nodes, including involvement by direct extension 
N2 Metastasis in ipsilateral mediastinal and/or subcarinal lymph node(s) 
N3 
Metastasis in contralateral mediastinal, contralateral, hiliar, ipsilateral or 
contralateral hiliar, ipsilateral or contralateral scalene, or supraclavicular lymph 
node(s) 
M – Distant Metastasis  
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M0 No distant metastasis  
M1 
Distant metastasis  
M1a Separate tumor nodule(s) in a contralateral lobe; tumor with pleural or 
pericardial nodules or malignant pleural or pericardial effusion 
M1b Single extrathoracic metastasis in a single organ (including involvement of a 
single nonregional node) 
M1c Multiple extrathoracic metastasis in a single organ or in multiple organs  
 
Table 6. LC staging with the correspondent TNM classification. Adapted from [25]. 
Primary  
Tumor (T)  
Regional Lymph 
Node (N) 
Distant Metastasis 
(M) 
Stage 
TX N0 M0 Occult carcinoma 
Tis N0 M0 0 
T1mi N0 M0 IA1 
T1a N0 M0 IA1 
T1a N1 M0 IIB 
T1a N2 M0 IIIA 
T1a N3 M0 IIIB 
T1b N0 M0 IA2 
T1b N1 M0 IIB 
T1b N2 M0 IIIA 
T1b N3 M0 IIIB 
T1c N0 M0 IA3 
T1c N1 M0 IIB 
T1c N2 M0 IIIA 
T1c N3 M0 IIIB 
T2a N0 M0 IB 
T2a N1 M0 IIB 
T2a N2 M0 IIIA 
T2a N3 M0 IIIB 
T2b N0 M0 IIA 
T2b N1 M0 IIB 
T2b N2 M0 IIIA 
T2b N3 M0 IIIB 
T3 N0 M0 IIB 
T3 N1 M0 IIIA 
T3 N2 M0 IIIB 
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T3 N3 M0 IIIC 
T4 N0 M0 IIIA 
T4 N1 M0 IIIA 
T4 N2 M0 IIIB 
T4 N3 M0 IIIC 
Any T Any N M1a IVA 
Any T Any N M1b IVB 
Any T Any N M1c IVC 
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APPENDIX IV 
Association between promoter’s methylation levels and clinicopathological features in BrC ccfDNA 
 
Table 7. Associations between BrC patients’ clinicopathological features and APC, FOXA1, MGMT, RARβ2, RASSF1A, SEPT9, SHOX2, SCGB3A1 and SOX17 promoters’ 
methylation levels. 
Genes APC FOXA1 MGMT RARβ2 RASSF1A SEPT9 SHOX2 SCGB3A1 SOX17 
Clinicopathological 
Features 
p value 
Histological 
Type 
0.483 0.423 0.949 0.409 0.351 0.357 0.725 0.279 0.141 
Estrogen 
Receptor 
Status 
0.341 0.697 0.685 0.975 0.090 0.564 0.726 0.478 0.675 
Progesterone 
Receptor 
Status 
0.826 0.358 0.586 0.590 0.031 0.439 0.769 0.513 0.285 
Molecular 
Subtype 
0.741 0.706 0.925 0.231 0.451 0.855 0.520 0.562 0.785 
Primary  
Tumor (T) 
0.398 0.926 0.773 0.445 0.134 0.138 0.567 0.529 0.275 
Regional  
Node (N) 
0.139 0.477 0.326 0.008 0.830 0.326 0.483 0.462 0.574 
Clinical  
Stage 
0.450 0.339 0.763 0.341 0.423 0.345 0.663 0.668 0.401 
p values obtained by Mann-Whitney Test for Estrogen Receptor Status, Progesterone Receptor Status and Regional Node (N), and by Kruskal-Wallis Test for Histological 
Subtype, Molecular Subtype, Primary Tumor (T), and Clinical Stage. Distant Metastasis (M) was not evaluated due to the low number of M1 patients. 
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APPENDIX V 
Association between promoter’s methylation levels and clinicopathological features in CRC ccfDNA 
 
Table 8. Associations between CRC patients’ clinicopathological features and APC, FOXA1, MGMT, RARβ2, RASSF1A, SEPT9, SHOX2, SCGB3A1 and SOX17 promoters’ 
methylation levels. 
Genes APC FOXA1 MGMT RARβ2 RASSF1A SEPT9 SHOX2 SCGB3A1 SOX17 
Clinicopathological 
Features 
p value 
Tumor 
Location 
0.808 0.499 0.325 0.192 0.499 0.201 0.120 0.501 0.054 
Primary  
Tumor (T) 
0.306 0.439 0.253 0.075 0.051 0.505 0.343 0.649 0.544 
Regional  
Node (N) 
0.601 0.270 0.382 0.179 0.828 0.720 0.355 0.418 0.908 
Distant  
Metastasis (M) 
0.028 0.569 0.191 0.863 0.826 <0.0001 0.011 0.733 0.024 
Clinical  
Stage 
0.202 0.963 0.462 0.901 0.387 <0.0001 0.131 0.585 0.152 
p values obtained by Mann-Whitney Test for Regional Node (N) and Distant Metastasis (M), and by Kruskal-Wallis Test for Tumor Location, Primary Tumor (T) and Clinical Stage. 
Histological type was not evaluated due to the low sample number of premalignant lesions and neurodocrine carcinoma. 
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APPENDIX VI 
Association between promoter’s methylation levels and clinicopathological features in LC ccfDNA 
 
Table 9. Associations between LC patients’ clinicopathological features and APC, FOXA1, MGMT, RARβ2, RASSF1A, SEPT9, SHOX2, SCGB3A1 and SOX17 promoters’ 
methylation levels. 
Genes APC FOXA1 MGMT RARβ2 RASSF1A SEPT9 SHOX2 SCGB3A1 SOX17 
Clinicopathological 
Features 
p value 
Histological 
Type 
0.005 0.724 1.00 0.035 0.369 1.00 0.292 0.166 0.229 
Primary  
Tumor (T) 
0.488 0.355 1.00 0.257 0.742 1.00 0.668 0.876 0.378 
Regional  
Node (N) 
0.141 0.267 1.00 0.500 0.018 1.00 0.210 0.837 0.185 
Distant  
Metastasis (M) 
0.321 0.200 1.00 0.243 0.082 1.00 0.633 0.297 0.029 
Clinical  
Stage 
0.405 0.174 1.00 0.354 0.271 1.00 0.845 0.771 0.142 
p values obtained by Mann-Whitney Test for Histological Type, Regional Node (N) and Distant Metastasis (M), and by Kruskal-Wallis Test for Primary Tumor (T) and Clinical 
Stage. For Histological Type, only Adenocarcinoma and Small-cell lung cancer were consider, since others subtypes presented a low sample number for statistical analysis.  
 
 
 
 
